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ABSTRACT
Cancer is defined as uncontrolled growth of abnormal cells bearing various molecular aberra-
tions. With the aid of massively parallel DNA sequencing technology, we can now comprehen-
sively characterize the genomic, epigenomic and transcriptomic landscapes of cancers. Subtypes
of cancer are continually being uncovered, often by clustering expression profiles or determining
driver mutations, the identification of which can be very important for prognosis and personalized
treatment plans. The goal of this dissertation is to develop and apply bioinformatics algorithms
to study subtypes of head and neck tumors. Using computational approaches, we both uncover
new subtypes, and investigate the oncogenic mechanisms of driving molecular events in the tu-
mor subtypes. My dissertation consists of three main chapters. In the first chapter, we present a
software program (PePr) for conducting the differential binding analysis of replicated ChIP-seq
data. PePr estimates the biological variation among samples and reports consistent changes across
sample groups. We use PePr to characterize the difference in histone modifications between two
human papillomavirus (HPV)-associated cancer cell lines and two non-HPV cell lines. In the sec-
ond chapter, we identify two robust HPV(+) head and neck squamous cell carcinoma subtypes
based on gene expression clustering. One subtype (HPV-KRT) shows more frequent genic viral
integration and splicing of E6, and reduced viral oncogenic E6 activity. The HPV-KRT subtype
also has more frequent copy number gains of chr3q, fewer losses of chr16q, and more PIK3CA
mutations. These genomic changes could potentially lead to the differences in gene expression
between the subtypes, including elevated immune response and mesenchymal differentiation in
HPV-IMU subtype, and up-regulated keratinocyte differentiation and oxidation-reduction process
xii
in HPV-KRT subtype. In the last chapter, we characterize the binding profile of a fusion oncogene,
PPFP (fusion of PAX8/PPARG; observed in 30% of follicular thyroid cancer) using ChIP-seq data
from a rat PPFP-transfected PCCL3 cell line. Our RNA-seq and ChIP-seq results suggest that
PPFP regulates many pathways related to cancer, and a PPARG agonist, pioglitazone, may reverse
the oncogenic effect of PPFP by altering oxidative stress. Altogether, we demonstrate how the
integrative analysis of high-throughput data can guide subtype discovery and mechanistic research
in cancer.
xiii
CHAPTER I
Introduction
1.1 Introduction
Cancer, which refers to any type of malignant tumor or neoplasm, is the second leading cause
of death in the US, and is expected to exceed heart disease as the leading cause of death within
the next few years (Rl et al., 2015). Approximately one in two men and one in three women will
develop cancer during their lifetime (Howlader et al., 2015). Typically, cancer is characterized as
uncontrolled division and growth of abnormal cells in a part of the body, and that has the potential
to spread to other parts of the body. These abnormal cells grow out of control, metastasize or
locally spread to other parts of the body, and gradually take over healthy tissues, causing the body
to lose normal functions and thus finally leading to death.
Cancer is probably one of the most complicated diseases, and its complicated nature comes in
many aspects. First, cancer can develop virtually anywhere in the body. Depending on the type(s)
of cell at the location of origin, cancers can be classified as: carcinoma (epithelial cells), sarcoma
(connective tissue), leukemia or lymphoma (hematopoietic cells), blastoma (embryonic tissue),
etc. The fact that cancer can arise in various cell types and locations implies a consensus disease
mechanism, whereas the dramatic difference in survival rates for different cancers illustrates its
heterogeneous nature. Second, the causes of cancer can be a mixture of genetic and environmental
factors, which cannot yet be fully disentangled. Known environmental risk factors include tobacco,
1
2alcohol, obesity, viral infection, and radiation. Some people are genetically predisposed to develop
certain types of cancer. For example, fanconi anemia (FA) is a rare genetic disease caused by
a mutation in a cluster of proteins involved in DNA repair. The relative risk of cancer in FA
is exceedingly high compared to the general population (Alter, 2014). Because oncogenesis is
inherently a chronic and sporadic process, it is extremely difficult to know which of the factors
directly causes cancer, thus compounding disease prevention.
A third reason is that at the molecular level, cancer is an orchestra of dysregulation of multi-
ple pathways. As reviewed in (Hanahan and Weinberg, 2000), transformation of normal cells to
cancer involves at least the following changes: (1) growth signal autonomy (2) apoptosis evasion,
(3) unbounded replicative potential, (4) sustained angiogenesis, and (5) tissue invasion (metasta-
sis). More recently, reprogramming of metabolism and immune evasion and were added as essen-
tial components of cancer (Hanahan and Weinberg, 2011). Furthermore, an enormous amount of
genome instability is observed in cancer, which may be the culprit for cancer cells to evolve and ac-
quire all of the aforementioned changes toward successful transformation (Hanahan and Weinberg,
2011).
Due to its formidable complexity, cancer has been perceived as incurable since its first appear-
ance in historical records centuries ago. This is no longer true, however, owing to advances and
innovations in treatments such as surgery, radiation and chemotherapy, and more importantly, bi-
ologic understanding of cancer. Tremendous progress has been made over the last few decades,
giving birth to new cancer drugs that target specific molecules and pathways, which hopefully
improve prognosis and reduce side effects. Driven by this promise of “precision medicine”, the
field is marching into the characterization of the molecular landscape of diverse cancers. Particu-
larly with the aid of high-throughput biomedical technologies, it is now possible to make unbiased
genome-wide high-throughput interrogations to begin to unveil the complex mysteries of cancer.
Since the introduction of DNA microarrays and subsequently second-generation massively-
3parallel sequencing, huge amounts of data have been generated. These two powerful tools en-
able a repertoire of microarray-based and/or sequencing-based measurements of cellular states.
These cellular states include the genome (the complete sequence of a sample, containing informa-
tion such as single nucleotide polymorphisms (SNP), translocations and copy number alterations
(CNAs)), transcriptome (expression levels of all genes), methylome (genome-wide methylation
status of cytosines), and regulome (genome-wide binding sites of transcription factors and histone
modifications). Thousands to millions of measurements are generated simultaneously, giving a
data-intensive snapshot of the cellular states in any given sample. These high-dimensional data
comprise a magnificent tool to study complex problems such as cancer biology. However, there is
no free lunch. Many challenges remain to accurately analyze such high-dimensional data and to
integrate several datasets to make insightful, clinically relevant inferences.
This dissertation focuses on the analysis of high-throughput molecular data from cancers that
histologically originated from the head and neck, and an effort to develop a novel bioinformat-
ics tool to analyze one type of these datasets. In this chapter, I will introduce the sequencing
technologies used in this dissertation, and review the discoveries of characteristic cellular states
of cancer revealed by high-throughput bioinformatics approaches, with an emphasis on head and
neck tumors. Finally, I will briefly summarize the contribution of the following chapters.
1.2 Background
1.2.1 High-throughput technologies
DNA microarrays remain the technology of choice for large-scale gene expression profiling
even now due to their cheap price, standardized analysis pipeline and small data volume. Microar-
rays have many applications beyond profiling transcriptomes, including array comparative genomic
hybridization (quantify CNA) and SNP-arrays (genotype SNPs and CNA). SNP-arrays are a type
of DNA microarray originally designed to genotype thousands of SNPs across the human genome.
4Surprisingly after a decade of development, this platform’s application has expanded to the de-
tection of large-scale copy number variations and loss-of-heterozygosity, which is very common
in cancer cells (LaFramboise, 2009). Microarrays, however, suffer from many limitations, despite
their utility in clinical research. For example, they can only measure genes/probes that are included
in the microarray, and their signal is sensitive to noise and various experimental conditions thus
causing many of the observations to be not readily reproducible. As a result, deep sequencing
based approaches were developed and are now preferred over microarray-based approaches.
Second-generation deep sequencing technologies can sequence millions of DNA molecules
in parallel. It is widely applied to genome resequencing, transcriptome profiling (RNA-seq),
DNA-protein interactions (ChIP-seq) and epigenome characterization (bisulfite-seq and ChIP-seq).
RNA-seq and ChIP-seq are two essential tools to learn the regulatory patterns of gene expression.
A typical analysis of both types of datasets is multilayered: the sequences are first mapped to a
reference genome, and then the mapped reads are counted over certain features (gene, enhancer,
or any genomic window). The resulting read counts are normalized and quantitatively compared
among individuals or between sample groups. Because the read counts are discrete numbers, they
are often modeled with Poisson or negative binomial distribution to account for additional vari-
ance. There have been many challenges for each of these steps, and therefore dozens of software
tools have been developed. For instance, most sequencing datasets suffer from small sample size,
thus small-sample inference and variance stabilization strategies are especially important. Com-
mon strategies for variance stabilization include borrowing information (variance) from genes that
have similar expression levels. Despite these sophisticated and computationally intensive analysis
steps, RNA-seq has many advantages over expression microarrays. For example, RNA-seq has a
higher dynamic range of signals, is more sensitive to lowly expressed genes, and has expanded
capabilities to discover and quantify unannotated transcripts and to detect expressed mutations
(Wang et al., 2009). ChIP-seq, short for chromatin immunoprecipitation followed by sequencing,
5uses antibodies to enrich DNA sequences from binding sites of a specific protein (transcription
factor or post-transcriptionally modified histone) for sequencing. After the sequencing reads are
aligned to the reference genome, reads will pile up at binding sites. The primary task of ChIP-
seq analysis is to identify these binding sites by determining regions that are statistically enriched
for reads compared to the background noise. A typical program would model the read counts as
Poisson or negative binomial distribution and test if the mean of one genomic window is greater
than that of the background. The signal strength for each binding site varies significantly, and the
signal-to-noise ratio is highly dependent on the efficiency of the antibody, thus making it difficult to
determine the optimal threshold and to separate the weak binding sites from the background noise.
The analysis is further complicated by the fact that there are three types of peaks (sharp, broad
and mixed) (Park, 2009). Typically, a ChIP-seq study of sufficient coverage (>50 million reads)
can uncover tens to hundreds of thousands of binding sites of a protein of interest. In addition, a
substantial portion of the transcription factor binding sites and histone marks are specific to cell
types or developmental stages, making differential binding analysis a necessary yet challenging
task.
Thousands of terabytes of sequencing data are being generated every year, presenting chal-
lenges for storage, computational power and novel analysis algorithms. Nevertheless, with the
aid of this technology, we can now routinely conduct genomic, epigenomic and transcriptional
profiling to explore the complex regulatory pathways in human biology and cancer.
1.2.2 Genomic aberrations and instability in cancer
Genomic instability is a hallmark of cancer, and can be manifested at different levels ranging
from as large as whole genome copy number alterations, to as tiny as single base substitutions.
The most profound change (even visible under a microscope) in cancer is aneuploidy, i.e., the
amplification/deletion of whole chromosomes. Because it is a common feature of many cancers,
6there has been an active area of research to identify its causes and roles in tumorigenesis (Hanks
et al., 2004; Schvartzman et al., 2010). In addition, focal copy number alterations (CNA) are
equally prevalent. It is estimated that in a typical cancer sample, 25% of the genome has arm-
level CNAs and 10% has focal CNAs, with 2% overlap (Beroukhim et al., 2010). There are some
arm-level “hotspot” CNAs, such as gains on 20q, 1q, 3q, 5p, 7q and 17q, and losses on 3p, 4q,
13q, 17p and 18q, but these recurrent changes are not necessarily present in all types of cancer
(Baudis, 2007). The large size of arm-level CNAs makes it difficult to identify the essential genes
for cancer transformation and outgrowth, however their recurrent nature across cancers suggests
that some additive effects may confer the cancer cells growth advantages. By contrast, studies
of the focal CNAs have pinpointed several oncogenes/tumor suppressors, suggesting that CNAs
play critical roles in activating and inactivating oncogenes and tumor suppressors, respectively, by
changing their expression dosages (Baudis, 2007; Eder et al., 2005; Lahortiga et al., 2007; Weir
et al., 2007; Zender et al., 2006). Positively selected CNAs, which likely contribute to cancer
progression, are suggested to recur across cancers at higher rates (Bignell et al., 2010; Kim et al.,
2013). For example, a pan-cancer analysis found that the most frequent focal CNAs include MYC
amplifications and CDKN2A/B deletions, each observed in 14% of all tumor samples (Beroukhim
et al., 2010).
Another notable structural rearrangement event in cancer is chromosomal translocation, which
leads to the juxtaposition of otherwise distant regulatory or coding DNA sequences between genes.
Since their first discovery in the early 1980s, inter-chromosomal translocations have been routinely
identified by guided approaches such as the chromosome banding analysis and fluorescence in situ
hybridization (FISH), which were then complemented by the development of microarray and deep
sequencing technologies due to their critical drawbacks (Mertens et al., 2015). Recently, more
than 8,600 different fusion transcripts were reported by mining the transcriptomic data from 4,366
tumors, from 13 different neoplasm types, within the Cancer Genome Atlas (TCGA) network
7(Yoshihara et al., 2015). Most of the events are passenger events (Mitelman et al., 2015). A few
gene fusions that have clinical relevance and have been extensively studied revealed two major
pathogenic mechanisms: (1) fusion of distant regulatory sequences to oncogenes leading to their
elevated expression, for example, fusion of immunoglobulin gene loci to MYC (Leder et al., 1983),
(2) creation of chimeric genes with abnormal activity (examples include chimeric BCR-ABL1 in
chronic meylogenous leukemia (CML) (Shtivelman et al., 1985) and TCF3-PBX1 in acute lym-
phoblastic leukemia (ALL) (Kamps et al., 1990)). However, the oncogenic mechanisms of many
more fusion genes (such as PAX8/PPARG in follicular thyroid cancer studied in this dissertation)
remain unclear. Recurrent gene fusions are strongly correlated with tumor subtypes, making them
ideal for diagnostic purposes in some types of cancer. Drugs that target gene fusions, such as ima-
tinib (against BCR-ABL1), have significantly improved the survival and quality of life for patients
(with CML, in the case of imatinib) (Druker, 2008).
The accumulation of single base substitutions and small insertions and deletions is also a com-
mon phenomenon in solid tumors. The source of mutations can be endogenous events, such as
erroneous DNA replication and mismatch repair, or exogenous factors such chemical mutagens or
radiation. On average, 33 to 66 genes show somatic mutations that alter their protein sequences
in common solid tumors (Vogelstein et al., 2013). Lung tumors and melanomas, which are ex-
posed to potent mutagens (cigarette and ultraviolet light), tend to harbor more mutations; tumors
with defects in DNA repair also have extraordinarily high mutational loads (Gryfe and Gallinger,
2001). As with CNAs and gene fusions, the majority of the somatic mutations are passengers rather
than drivers. The study of well-known oncogenes and tumor suppressor genes reveals nonrandom
and highly characteristic patterns of mutations. That is, mutations in oncogenes tend to recur
at the same amino acid positions, whereas tumor suppressor genes are often mutated by protein-
truncating substitutions throughout their length. This rule can be used to accurately classify a driver
gene as an oncogene or tumor suppressor gene. A total of 125 driver genes were designated by a
8stringent rule described in Vogelstein et al. (2013). This list includes 71 tumor suppressor genes
(TP53, APC, RB1, WT1, etc) and 54 oncogenes (KRAS, BRAF, ID1, EGFR, PIK3CA, etc). The mu-
tated driver genes can be grouped into a few signaling pathways related to cell survival, cell fate
determination and genome maintenance, all of which are vital for cancer progression. Progress
made in characterizing cancer genome perturbations has spurred development of genome-based
medicine that target certain activating oncogenes and pathways. A representative example is the
use of EGFR kinase inhibitor to treat cancers with an EGFR mutation (Sharma et al., 2007). How-
ever, targeting tumor suppressors and oncogenes other than kinases, and avoiding the development
of drug resistance, remain challenging tasks.
1.2.3 Epigenetic dysregulation in cancer: DNA methylation and histone modifications.
Beyond genomic instability, the epigenetic landscape is also profoundly altered in cancer. Epi-
genetic switches, including DNA methylation and histone modification, play pivotal roles in mod-
erating nuclear structure, accessibility to DNA and gene activity. Tumor cells often undertake a
massive global loss of DNA methylation, mainly in the gene body, intergenic regions and repeti-
tive DNA sequences, but also frequently acquire hypermethylation at certain promoters and in CpG
islands (Esteller, 2005; Feinberg and Tycko, 2004; Herman and Baylin, 2003). Silencing tumor-
suppressor genes via promoter hypermethylation is an important mechanism in tumorigenesis. For
instance, the cell cycle inhibitor CDKN2A, DNA repair genes MLH1, MGMT, and BRCA1, and
dozens of other tumor-suppressor genes have been shown to be silenced by DNA hypermethyation
in cancer (Esteller, 2007). In contrast, the cause and consequences of global hypomethylation is
still poorly understood. There is evidence that active demethylation through a hemimethylated in-
termediate may play important role in DNA hypomethylation in cancer (Ehrlich, 2009). It has also
been hypothesized that the hypomethylation could be linked to genomic instability, reactivation of
transposable elements, and loss of imprinting (Esteller, 2005).
9DNA wraps around histones and form nucleosomes, the basic unit for chromatin. There is a
multitude of post-translational modifications (PTMs, including acetylation, methylation, phospho-
rylation and so on) at different amino acid locations of the tails of histone proteins (H2A, H2B,
H3 and H4). Each histone modification can be dynamically added or removed by specific en-
zymes. Certain combinations of PTMs are often identified together; these signatures are called the
“histone code”, and serve as important platforms for controlling cellular processes such as gene ex-
pression, DNA replication, and chromosome condensation (Strahl and Allis, 2000; Turner, 2000).
Deregulation of histone-modifying enzymes is a hallmark of human cancer, suggesting that altered
histone PTMs have important roles in cancer development. For instance, global loss of acetylation
of histone H4 at lysine 16 (H4K16ac) and trimethylation of histone H4 at lysine 20 (H4K20me3)
were first reported at repetitive DNA sequences in multiple primary tumors (Fraga et al., 2005).
With the aid of ChIP-seq assays, dysregulation of various other histone PTMs are being discovered
and linked to tumor progression and prognosis, including H3K4me3, H3K27me3, H3K9ac/me3,
H3K56ac, etc (Fu¨llgrabe et al., 2011). Dysregulated histone modifications are associated with
changes in gene expression, silencing at heterochromatin domains, cell cycle checkpoint instability
and impaired DNA repair (Fu¨llgrabe et al., 2011). It has also become evident recently that histone
modification and DNA methylation can be dependent on each other during normal development
and tumorigenesis, mediated through the interaction between histone and DNA methyltransferases
(Cedar and Bergman, 2009).
1.2.4 Discovery of molecular cancer subtypes: distinct etiology and prognosis.
Cancer is heterogeneous in the sense that every patient, and even every tumor is a different
molecular entity. Traditionally, cancer subtypes were defined by morphological and histological
features. However, this classification regime can be very inaccurate and cannot sufficiently cap-
ture the heterogeneity underlying the tumor. The fact that every tumor harbors distinct somatic
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mutations, CNAs, and epigenetic changes has driven the treatment of cancer into the new era of
precision medicine (Garay and Gray, 2012). Some driver mutations and gene fusions occur so
frequently in cancers that they are used to define cancer subtypes. Adjuvant therapies with chem-
icals specifically targeting these aberrations greatly improve the outcome of the patients bearing
the mutations or gene fusions. For instance, ABL1 translocation (in CML and ALL), EGFR muta-
tion/amplification (Glioma and lung cancer) and BRCA1/2 mutation (Breast, ovarian and pancre-
atic cancer) define distinct tumor subtypes that can be successfully targeted by therapeutic agents
(Druker and Guilhot, 2006; Fong et al., 2009; Iyer and Bharthuar, 2010). Cancer subtypes can also
be defined using high-throughput data features such as transcription profiling of coding and non-
coding RNAs, methylation patterns, and protein levels. Subtype discovery using mRNA expression
patterns is widely used in most cancer types, particularly for large datasets generated by the Cancer
Genome Atlas (TCGA) (The Cancer Genome Atlas Research Network, 2011; The Cancer Genome
Atlas Network, 2008; Taylor et al., 2010). The subtypes defined by transcriptional profiles in some
cancers are suggestive of distinct subtype etiology and strongly associated with disease outcome
(van’t Veer and Bernards, 2008).
1.2.5 The biology of head and neck tumors
Head and neck tumors include several categories of cancers with different origins. The two
main categories investigated in this dissertation are (1) head and neck squamous cell carcinomas
(HNSCC) of the oral cavity, oropharynx and larynx, and (2) thyroid gland tumors.
HNSCC is the sixth most common non-skin cancer worldwide with 600,000 incidences each
year and a five-year mortality rate of 37 to 62 percent (Ferlay et al., 2010; Vokes et al., 1993). HN-
SCC is about three times more common in men than women (Ferlay et al., 2010). The major known
risk factors for HNSCC are tobacco, alcohol, and infection with high risk human papillomavirus
(HPV). Extensive studies of HPV in cervical cancer (99% of which are caused by HPV) have
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shown that the oncogenic potential of HPV can mainly be attributed to two early viral genes, E6
and E7. E6 leads to the degradation of tumor suppressor protein p53, and E7 sequesters retinoblas-
toma (Rb), which cooperatively suppress apoptosis and promote tumor cell growth and prolifer-
ation (Moody and Laimins, 2010). HNSCC tumors associated with HPV have distinct molecular
profiles and better treatment responses than non-HPV tumors (Leemans et al., 2011). HPV as-
sociated tumors are dominated by activating mutations of the oncogene PIK3CA, loss of TRAF3,
elevated expression of p16 (CDKN2A), and amplifications of E2F1. The former two genes point to
aberrant activation of NF-κB pathway, whereas the latter two are linked to cell cycle regulation. In
contrast, common features in smoking-related HNSCCs are loss-of-function TP53 mutations, inac-
tivation/truncation of CDKN2A, and frequent copy number alterations (The Cancer Genome Atlas
Research Network, 2015). Transcription and methylation profiling also demonstrate numerous dif-
ferences between HPV and non-HPV tumors. Clustering based on these genome-wide profiles in
multiple studies has identified four to five distinct molecular subtypes that may be useful in guiding
novel biomarker development (Chung et al., 2004; The Cancer Genome Atlas Research Network,
2015; Seiwert et al., 2014).
Thyroid cancer is the most common endocrine malignancy and is three times more frequent in
women than men (Rl et al., 2015). The incidence of thyroid cancer has nearly doubled worldwide
since 2000, possibly due to combination of more frequent use of sensitive diagnostic tools such
as ultrasound and FNA (fine needle aspiration biopsy) and a true increase as a consequence from
increased exposure to radiation (Pellegriti et al., 2013; Zevallos et al., 2015). Thyroid cancers are
transformed from thyroid follicular or parafollicular cells and are well-differentiated in most cases.
Papillary thyroid carcinoma (PTC) accounts for 80% of all thyroid tumors, and most PTCs have
good prognosis after treatment. In contrast, a subset of follicular thyroid carcinomas (FTCs) are
often more aggressive and less responsive to therapy. 60-70% of PTCs harbor one of a few aber-
rations, such as RET-rearrangements, or RAS or BRAF mutations (Vu-Phan and Koenig, 2014).
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For a subset of FTC (∼ 30%), a notable tumorigenic event is the fusion protein (PPFP) of two
transcription factors, PPARG and PAX8 (Kroll, 2000). Several in vitro studies have shown that
PPFP acts as an oncogene (Au et al., 2006; Espadinha et al., 2007; Gregory Powell et al., 2004).
However, additional studies are required to uncover its interacting partners and the population of
genes and pathways it regulates.
1.3 Dissertation overview
Dozens of high-throughput datasets have been generated in the public domain and here at the
University of Michigan to begin to understand the complex molecular architecture of head and
neck tumors. As reviewed in the previous sections, each tumor cell population has a combination
of a few frequent genetic or epigenetic aberrations, which can be grouped to define subtypes of
cancers. This is also called inter-tumor heterogeneity. Discovery of the cancer subtypes is crucial
to decomposing the complex oncogenic pathways leading to cancer, and will lay the foundation
for developing biomarkers and therapies that are tailored to a specific cancer subtype. The goal
of this dissertation is to develop and apply bioinformatics algorithms to uncover the inter-tumor
heterogeneity (subtypes) of head and neck tumors, and investigate the oncogenic mechanisms of
the tumor subtypes.
In chapter II, we develop a novel pipeline to enable the differential binding analysis of repli-
cated ChIP-seq data. ChIP-seq is a relatively new innovation that can be used to map the locations
of post-transcriptional modifications (PTM) of histones, the dysregulation of which are frequently
observed in cancer. Identification of differential binding sites of histone PTMs between cancer and
normal tissue or between subtypes of cancer is a critical step to characterize their epigenetic differ-
ences. There is substantial individual difference between cancer samples, which is not the essential
change associated with each subtype. To remove sample biases, biological replicates are often re-
quired for ChIP-seq studies. Although more than a dozen ChIP-seq software tools exist, at the
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time of publication of our software, none of them were specifically designed to analyze data with
replicates. Consequently, ChIP-seq datasets with replicates could only be processed with subopti-
mal methods. Inspired by the successful application of the negative binomial model for RNA-seq
data, we developed a similar model for ChIP-seq data with several innovated optimization steps
specific for ChIP-seq, such as window size estimation, signal normalization, variance stabiliza-
tion through kernel smoothing, and artifact removal. The whole pipeline is called Peak calling
Prioritization (PePr) pipeline. We demonstrated our superior performance by comparing PePr to
existing approaches. We also applied our method on histone PTM data from HNSCC cell lines to
successfully characterize the differences of H3K27me3 binding profiles between HNSCC subtypes
defined by HPV status. PePr is also applicable to other DNA-seq datasets, such as affinity-based
DNA methylation and hydroxymethylation data. All together, this pipeline will be a useful tool for
characterizing the epigenomic landscapes of cancers and cancer subtypes.
Chapter III concentrates on subtype discovery and characterization of HPV(+) HNSCCs. HPV
associated HNSCCs are less characterized than their non-HPV counterparts, due to their com-
mon exclusion, unknown status, or small numbers in relevant studies. Although HPV(+) patients
overall have better prognosis, heterogeneity in terms of clinical outcomes and biology remains.
De-escalated therapies have been proposed for HPV(+) patients to reduce unnecessary treatment-
induced morbidity, however, heterogeneity within this patient subgroup has to be examined to
distinguish aggressive tumors from easily treated ones before clinical decisions are made. In addi-
tion, the incidence of HPV(+) HNSCC has been steadily increasing in developed countries such as
United States, whereas the number of HPV(-) HNSCC cases has decreased. Although the use of
HPV vaccine is expected to reduce the prevalence of HPV(+) HNSCC caused by the most common
high-risk HPV types, it will be many years before the effects are seen. Instead of just relying on the
vaccines, the research on HPV(+) HNSCC tumors is still clinically important. In this chapter, we
aimed to characterize the heterogeneity within HPV(+) HNSCCs by mining RNA-seq and SNP-
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array data. We identified two robust HPV(+) HNSCC subtypes using gene expression-based clus-
tering, and characterized the differences in transcriptional and genomic profiles (including copy
number alterations and genic mutations) and HPV characteristics between the two subtypes. We
found that one subtype (HPV-KRT) has more keratinization, viral integration events, and spliced
E6*, and less full length E6 activity, immune activity, and chr16q deletions. HPV-KRT also has
more frequent chr3q amplifications and PIK3CA mutations. Literature concerning all of these fea-
tures except keratinization suggest a worse outcome for this subtype, thus we hypothesized that
HPV-KRT would have a lower survival rate. This expected trend was observed in The Cancer
Genome Atlas survival analysis, although it was not statistically significant. Our study provides
valuable insight into the key genetic events that likely drive two different paths to (or stages of)
oncogenesis of HPV(+) HNSCCs, which will be important for the development of new biomarkers
and therapies for HPV(+) patients.
In Chapter IV, we investigated the oncogenic mechanism of the fusion protein PPFP, which is
associated with a subset of follicular thyroid cancer (FTC). The fusion protein PPFP is a fusion of
two transcription factors, PPARG and PAX8. As reviewed in the previous section, PPFP is one of
the major genetic changes found in FTC (accounting for 30% of the cases). PPFP shows oncogenic
effect in vitro (inducing cell division and repressing apoptosis) (Au et al., 2006; Espadinha et al.,
2007; Gregory Powell et al., 2004), and may be a potential therapeutic target for PPFP-associated
FTC. Pioglitazone, a PPARG agonist, shows strong therapeutic effect in a mouse model of PPFP
FTC, significantly shrinking the primary tumor and preventing metastasis (Dobson et al., 2011).
However, the oncogenic function of PPFP and therapeutic effect of pioglitazone were poorly un-
derstood. In this chapter, we characterized the genomic binding sites of PPFP using ChIP-seq and
showed that PPFP retains the binding ability of both original transcription factors, PPARG and
PAX8, in the rat PPFP transfected PCCL3 cell line. Combined with RNA-seq data, we showed
that PPFP binds to and regulates the expression of genes involved in multiple cancer-related pro-
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cesses. PPFP binds to adipocyte genes in preference to macrophage genes, and the adipogenic
effect was greatly enhanced in the presence of pioglitazone. In addition, enlightened by RNA-seq
discovery, we designed experiments to confirm that PPFP induces oxidative stress in thyroid cells
and pioglitazone further increases susceptibility to oxidative stress, which may eventually lead to
cell death. Our data highlights the complexity of PPFP as a fusion transcription factor and various
ways it regulates thyroid oncogenesis.
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CHAPTER II
PePr: a peak-calling prioritization pipeline to identify
consistent or differential peaks from replicated ChIP-Seq data
2.1 Introduction
Chromatin immunoprecipitation followed by massively parallel sequencing (ChIP-seq) is the
standard technique to identify the genome-wide occurrences of transcription factor (TF) binding
sites and histone modifications in vivo. Over the past few years, there has been tremendous de-
velopment of analysis methods for ChIP-seq data, with tens of ‘peak finders’ published (Blahnik
et al., 2010; Boyle et al., 2008; Fejes et al., 2008; Jothi et al., 2008; Kornacker et al., 2012; Qin
et al., 2010; Rashid et al., 2011; Rozowsky et al., 2009; Song and Smith, 2011; Valouev et al., 2008;
Wang et al., 2013; Xu et al., 2010; Zang et al., 2009; Zhang et al., 2008). Over this course,several
characteristics of ChIP-seq datasets, such as enrichment profile features (peak width, signal-to-
noise ratio and location relative to genomic features) of different types of TFs and histone modi-
fications, sources of artifacts and the commonly observed statistical distributions of read counts,
have been gradually revealed (Park, 2009; Pepke et al., 2009; Rye et al., 2011). As sequencing
cost decreases, use of biological replicates is emerging and may eventually become the standard
practice for ChIP-seq studies. Most of the Encyclopedia of DNA Elements (ENCODE) consor-
The work presented in Chapter II is published as Zhang Y*, Lin YH*, Johnson TD, Rozek LS, Sartor MA.
“PePr: a peak-calling prioritization pipeline to identify consistent or differential peaks from replicated ChIP-Seq
data.” Bioinformatics. 2014 Sep 15;30(18):2568-75. doi: 10.1093/bioinformatics/btu372 (*equal contribution)
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tium data were performed in duplicate (Landt et al., 2012). Furthermore, as researchers shift from
performing ChIP-seq experiments that address mechanistic questions to those that hypothesize dif-
ferential and/or context-specific binding in a disease, treatment or epidemiologic setting, the use
of replicates to account for individual variability becomes crucial. We expect that this will lead
to more analyses comparing a group of ChIP samples with a group of controls, or two groups of
ChIP samples, with or without controls, run under different experimental conditions. ChIP-seq
peak finders that perform direct group comparisons within the peak-calling pipeline are currently
lacking. When biological replicates are available, researchers may choose to combine the repli-
cates (CR) in each group and run one-ChIP-versus- one-control analysis to identify all possible
peaks. Alternatively, they can pair ChIP and control samples, conduct a separate analysis (SA) for
each pair and then stipulate rules to combine the peak-finding results, such as requiring the peaks
to be found in all pairwise comparisons. The CR approach is often used in TF ChIP-seq studies
to identify all possible binding sites. However, if the goal is to find consistent binding among
replicates, many false positives may occur where binding is present in only one or a subset of the
samples. The SA approach is more sophisticated in the sense that it does not lose all information
regarding sample-to-sample variability and is more applicable to experiments that have a natural
pairing of samples. However, because it evaluates peaks for each replicate separately, the effects of
false negatives across replicates may become compounded. Thus, the SA approach is more likely
to miss moderate, yet consistent, differences in binding. When there is no inherent pairing between
test and control samples, as often occurs with differential binding analyses, the SA approach may
call a peak because in each one-versus-one analysis, one sample has greater enrichment than its
paired sample. Yet, if the pairs were constructed differently, some ’peaks’ may no longer exist.
An alternative approach is the irreproducible discovery rate (IDR) (Landt et al., 2012) approach
recommended by ENCODE. IDR can be considered a sophisticated CR approach, which assesses
the consistency of peak rankings in replicates to find an optimum significance cutoff for determin-
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ing the final peak list. Correctly modeling the variation among samples in gene expression studies
when testing for differential expression has been shown to be of great importance (Anders and
Huber, 2010; Robinson et al., 2010; Sartor et al., 2006). For RNA-Seq analysis, several methods
[for example, edgeR (Robinson et al., 2010) and DESeq (Anders and Huber, 2010)] use a negative
binomial distribution instead of a Poisson distribution to capture the extra variance among repli-
cates. These approaches can be used with ChIP-seq data; however, they do not perform the first
several steps of the ChIP-seq analysis pipeline nor do they take advantage of local chromosomal
information. An exact negative binomial test (diffReps) was recently introduced for ChIP-seq data
and compared with edgeR and DESeq using two histone modification datasets (Shen et al., 2013).
Other approaches to identify differential binding with replicates include the R packages DiffBind
(Ross-Innes et al., 2012) and DBChIP (Liang and Keles, 2012a); although these programs take into
account sample variation, they rely on other peak callers to generate peak sets for each individual
sample first and conduct analysis on the candidate regions that fall within the peak sets.
Here, we introduce a ChIP-seq peak-finding and prioritization (PePr) pipeline that can analyze
either a group of ChIP-seq samples together with controls or compare two groups of ChIP-seq
samples, with or without controls. PePr uses a sliding window approach and models read counts
across replicates and between groups with a local negative binomial model. Genomic regions with
less variable read counts across replicates are ranked more favorably than regions with greater
variability, thus prioritizing consistently enriched regions. We tested PePr on ChIP-seq data for
activating transcription factor 4 (ATF4) (Han et al., 2013), seven ENCODE TF datasets and one
histone modification data- set (H3K27 tri-methylation), and compared the performance of PePr to
several ChIP-seq methods representing different statistical models and using different sources of
information: MACS (Zhang et al., 2008),MACS2 and SPP (Kharchenko et al., 2008) with IDR
(Landt et al., 2012), ZINBA (Rashid et al., 2011), SICER (Zang et al., 2009), diffReps (Shen
et al., 2013), DiffBind (Ross-Innes et al., 2012) and edgeR (Robinson et al., 2010).We show that
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PePr performs favorably compared with the other tested approaches, prioritizing peaks that reflect
stronger enrichment fold and higher consistency among samples.
2.2 Methods
2.2.1 Datasets
ATF4 data
ATF4 data were previously published (Han et al., 2013). Briefly, samples were obtained from
mouse embryonic fibroblasts from transgenic mice after 8h treatment with tunicamycin, including
three ATF4 wild type ChIP samples and three ATF4 knockout ChIP samples, which served as the
controls. Data were obtained from Gene Expression Omnibus (GEO) with the accession number
GSE35681.
ENCODE TF data
Neuron-restrictive silencer factor (NRSF), CCCTC-binding factor (CTCF), GA-binding pro-
tein (GABP), nuclear respiratory factor 1 (NRF1), structure maintenance of chromosome 3 (SMC3),
upstream stimulatory factor 1 (USF1) and USF2 were downloaded from the UCSC collection of
ENCODE ChIP-seq data.
H3K27me3 data
ChIP-seq using two human papillomavirus (HPV)-positive and two HPV-negative squamous
cell carcinoma (SCC) cell lines were performed. Cell lines were cultured as previously described
(Sartor et al., 2011), and chromatin immunoprecipitation using HistonePathTM (Active Motif) for
the commercial-quality antibody pull downs for H3K27 tri-methylation and library preparation
were performed by GenPathway, Inc. (part of Active Motif, Carlsbad, CA). DNA was amplified
according to the Illumina ChIP-seq library construction protocol, and a region of 250350bp was
excised from the preparative Agarose gel. Sequencing of the four immunoprecipitated samples and
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four input DNA samples was performed at the University of Michigan DNA sequencing core using
the Illumina HiSeq with 50 base single-end reads. Data were deposited in GEO with accession
number GSE38629. Raw reads were aligned to hg19 using BWA (Li and Durbin, 2009) with the
default parameters. The numbers of peaks called are listed in Table 2.1.
2.2.2 PePr algorithm
preprossing of data
Removal of duplicated reads (optional): For every sample, PePr offers the option to remove the
duplicated reads mapped at the same genomic location. Sometimes the same DNA fragments can
be sequenced repeatedly due to PCR amplification or library preparation and are over-represented
in the library. Assuming each piece of DNA in the genome has equal probability of being se-
quenced, then the occurrence of the same sequence read multiple times would be low and would
depend on the sequencing depth. Therefore, PePr removes extra duplicated reads that are beyond
the expected maximum at each genomic location. The maximum is calculated using a binomial
distribution as specified in (Zhang et al., 2008).
Fragment length estimation: PePr estimates the shift size (half of the DNA fragment length)
for each ChIP sample and shifts all reads to their 3’ direction by this amount. For single-end ChIP-
seq data, since the sequencing read length is shorter than the DNA fragment length, the cluster
of forward-strand reads and that of reverse-strand reads at the binding sites show a phase lag.
Properly shifting both strands of reads towards the center of the DNA fragment can improve the
power and precision of detecting binding sites. For each chromosome, PePr shifts all the reads by
several attempted shift sizes (starting at zero and increasing base by base), and counts the overlap
between reads from forward and reverse strands. The shift size which maximizes the overlap is
the optimum shift size. For every ChIP sample, the median of the estimated shift sizes from five
chromosomes (chr1 to chr5) is calculated and used. We use the median from five chromosomes
to balance speed and robustness against potential outliers; the shift sizes estimated from these five
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chromosomes have been consistent for all datasets tested thus far. If control samples are included
in the analysis, the average shift size derived from the ChIP samples are applied to the controls.
Window size estimation: To divide the genome into windows, a recommended window size is
calculated as the estimated average width of the peaks, allowing PePr to optimally capture the reads
in peak regions. To achieve this goal, we first divide the genome into non-overlapping 20bp bins.
For each chromosome, the bin with the largest number of reads is chosen as the seed and extended
to the flanking bins until a bin is reached which has less than 10% of the reads in the seed bin.
The combined width of these bins is recorded. The abovementioned process is repeated 100 times
after which the median of the widths is calculated. The median of widths for all chromosomes is
the recommended window size. The genome is then divided into windows of the chosen (either
recommended or user-specified) size that overlap by 50% and the number of reads in each window
is multiplied by the normalization constant for each sample.
Normalization: The total number of reads often varies among samples, and the immunoprecip-
itation efficiency can also differ substantially among ChIP samples, which may artificially increase
the variation among samples if unnormalized, raw read counts are used. Currently, PePr uses the
Normalization of ChIP-seq (NCIS) method (Liang and Keles, 2012b) to normalize input (control)
samples and a modified Trimmed Mean of M values (TMM) method to normalize ChIP samples
(Robinson et al., 2010). First, PePr splits the genome into 1000bp bins. The mean of all ChIP li-
braries is used as the reference sample, towards which every sample will be normalized. For every
input sample i versus the reference r, let nig and nrg be the number of reads in the gth genomic bin
for the input and reference samples, respectively. The normalization factor for the input sample is
calculated as
rˆ =
∑
g∈B nrg∑
g∈B nig
(2.1)
where B represents the background bins (in which no enrichment by the antibody exists). Let
ng = nrg + nig, Given background bins are more likely to have lower numbers of reads, we define
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B = {g : ng ≤ tˆ}, where the count threshold tˆ is the smallest t for whichB consists of>0.75 of the
genome; this percentage was used and tested in (Liang and Keles, 2012b), and works well as long
as the DNA binding protein does not bind to >25% of the genome. Finally, the number of reads in
each window for the input sample is multiplied by its normalization factor, rˆ. The process is then
repeated for each input sample. To normalize the ChIP samples for different immunoprecipitation
efficiencies, for each ChIP sample, c, versus the reference r, the bin-wise log fold change for the
gth genomic bin is defined as
Mg = log2(
nrg
ncg
) (2.2)
and the geometric mean of log read counts is defined as
Ag =
1
2
log2(nrg · ncg) (2.3)
Where nrg and ncg are the raw read counts in the gth bin of the reference sample and target
ChIP sample, respectively. The trimmed mean of Mg values (TMM) is calculated as the weighted
average of Mg after removing the upper and lower x percentages of data (based on both Mg and
Ag) as described in (Robinson et al., 2010). The default trimming percentages for Mg and Ag are
20% and 5% respectively. For Mg, 20% is a conservative estimate to exclude the differential sites,
whereas for Ag, 5% is used to remove the highest and lowest signal regions where there may be a
high percent of artefacts. The log fold change, Mg, is weighted by the mean log read counts. Thus,
log2(TMMc) =
∑
g∈G∗ AgMg∑
g∈G∗ Ag
(2.4)
where G∗ denotes the remaining bins after the trimming. Since we aim to normalize for the dif-
ference in antibody efficiency among the ChIP samples, the normalization constant should be esti-
mated only from enriched regions. Inclusion of background bins will bias the estimator towards the
library ratio (e.g., if all bins were used the estimator would equal the library total read count ratio).
In practice, the number of enriched regions varies across different TFs and it may not be clear how
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many bins should be included before we have formally called the peaks. To overcome this uncer-
tainty, PePr sorts the bins by ng = nrg+ncg and estimates the TMM from the largestN bins, where
N is a vector of values ranging from 1,000 to 50,000 (1000, 5000, 10000, 20000, 30000, 40000,
50000; the range was set based on the number of peaks observed for common TFs and histones).
From the several TMMs estimated from the different Ns, the one that is most different from the
library ratio is reported. This will be close to the optimal TMM because as N increases toward the
true number of peaks, the TMMs trend away from the library ratio, approach the enrichment signal
ratio, and then eventually return to converge to the library ratio as N surpasses and grows beyond
the true number of peaks. Plots illustrating the steps of this normalization process are available on
our website at http://code.google.com/p/pepr-chip-seq/.
Detection of significant windows
Read counts in the test and control sample groups (or two ChIP sample groups) are modeled
using the negative binomial distribution as described here. Let Yijk denote the observed number of
reads in the ith genomic window(i = 1, . . . , I), the jth replicate(j = 1, . . . , Jk) and kth group(k =
1, 2). Assuming a negative binomial distribution, we have
Yijk ∼ NB(µi·k, ψ) = Γ(yijk + ψ
−1)
Γ(ψ−1)Γ(yijk + 1)
ψ−1ψ
−1
µ
yijk
i·k
(ψ−1 + µi·k)(ψ
−1+yijk)
(2.5)
whereµi·k = E(Yijk) and ψ is the dispersion factor (as ψ → 0, the distribution converges to a
Poisson distribution). By parameterizing the means of read counts for each window i as µi·1 = µi·
and µi·2 = γµi·, we can test for a significant difference between two groups by testing the following
hypothesis:
H0 : γ ≤ 1vsH1 : γ > 1
In the case of test (ChIP) versus control comparisons, the controls are assigned as group 1 and
test samples are group 2 so only one direction of the hypothesis will be tested; whereas in the case
of two ChIP group comparisons (i.e. differential binding), a sample/group swap is performed and
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the hypothesis is tested both ways automatically. The local dispersion parameter is estimated for
each window using a weighted average of initial dispersion estimates from local windows in order
to gain more robust estimates as described here. The log-likelihood for a given window is:
li(ψ) =
2∑
k=1
Jk∑
j=1
[log Γ(yijk + ψ
−1)− log Γ(ψ−1)− log Γ(yijk + 1)+
ψ−1 log(ψ−1) + yijk log(µ̂i·k)− (ψ−1 + yijk) log(ψ−1 + µ̂i·k)]
(2.6)
where µ̂i · k =
∑Jk
j=1 yijk
Jk
The local dispersion estimator ψˆ maximizes the log likelihood over W nearby windows (including
the current window) using the triangular weight:
L(ψ) =
W∑
x=−W
(1− |x|
w + 1
)li+x(ψ) (2.7)
The use of a local dispersion estimator provides a stable estimator of the dispersion factor
when the sample size is small. W is one for the SHARP peak setting and ten for the BROAD peak
setting, based on observations of autocorrelation in multiple datasets. To calculate the significance,
we use an asymptotic Wald’s test with log transformation. We can define:
Zi =
[g(γˆ)− g(γ0)]
g′(γˆ)σ̂γˆ
=
[log(γˆ)− log(γ0)]γˆ
σ̂γˆ
(2.8)
Where Zi has an asymptotic standard normal distribution,γˆ = yˆ/xˆ, γ0 = 1, and σ̂γˆ is defined as
σ̂γˆ =
√
y¯[J1x¯(ψˆ−1 + y¯) + J2y¯(ψˆ−1 + x¯)]
J1J2ψˆ−1x¯3
(2.9)
where x¯ =
∑J1
j=1 yijk
J1
and y¯ =
∑J2
j=1 yijk
J2
P-values are calculated using Zi as the test statistic. Windows satisfying the specified p-value
cutoff (the default is1e-5) are called as significant windows. Benjamini-Hochberg FDR is also
reported.
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Defining peak regions and post-processing of peaks
The significant windows that are localized in the same genomic area are merged. PePr has two
different settings for merging windows; the maximal merging distance is smaller for the SHARP
peak setting and larger for the BROAD peak setting (to ensure that the broad histone peaks are
not broken into multiple enrichment regions in a given area). Generally in an explorative analysis
when the enrichment shape of the peak is unknown to the user, the latter BROAD peak setting is
recommended.
Optionally, PePr can remove peaks due to a high level of PCR duplicates in ChIP samples.
Those peaks show no strand lag between forward and reverse strand reads (Landt et al., 2012) and
are very likely to be false positives; a high proportion of these peaks in the final peak list is an
indicator of poor data quality. Removing these artifacts requires accurate estimation of the shift
size, otherwise we will be risking removing true positives. Fortunately, these artifacts also occur
in a properly prepared control sample, displaying similar read profiles. Thus, PePr tackles this
issue by removing peaks that have similar shape in both the ChIP and input samples. Specifically,
for each peak, let pixk be the proportion of reads in the peak at nucleotide position x for group k,
where k = 1 is the ChIP group and k = 2 is the input group. Reverse-strand reads are counted
at their 3’ end. Thus, for each group k,
∑
x∈P pixk = 1, where P is the entire set of positions in
the peak region. The minimum of the ChIP and input proportion at each position is determined,
and the resulting values are summed to define the value R across all positions in the peak using the
formula:
R =
∑
x∈P
min(pix1, pix2) (2.10)
R ranges from 0 to 1, and will have a high value when the peak shape is similar between ChIPs
and controls; based on observations, technical artifacts typically have a high R value greater than
0.5, whereas R values for most (true) peaks are distributed between 0 and 0.2. PePr removes the
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peaks having R value greater than 0.5.
Additionally, PePr evaluates the overlap between forward-strand reads and reverse-strand reads
(counted at their 3’ end) before and after shifting. A peak with strand-overlap-ratio that is high
(>0.2) before shifting and decreases significantly after shifting (decrease >50% of the original
level) is removed by PePr. Most PCR-duplicate peaks simultaneously meet both of the two criteria
defined above. These removed peaks are reported in a separate file.
Finally, PePr offers the option to refine the peak width for sharp peaks. Typically for TFs,
downstream analysis such as motif analysis works optimally with a fine resolution of the peaks
(i.e. reduced to minimal width that may contain the core protein-protected binding region). In an
ideal (hypothetical) ChIP experiment, the core DNA binding site would be between the last start-
ing position of the forward-strand reads and the first starting position of the reverse-strand reads.
However, real-life ChIP-seq experiments are “contaminated” substantially by the background se-
quences (the percentages were observed to vary from 30% to close to 100% of the library (Liang
and Keles, 2012b) ) and complicated by other technical factors influencing mappability and se-
quencability. Therefore, we use a more robust method to narrow the peak width without losing the
protected region by setting the left boundary to be at the 20% quantile of the starting position from
the forward-strand reads and the right boundary to be at the 80% quantile of the starting position
from the reversestrand reads. These percentages are conservatively chosen.
Differential peak binding: the differential binding analysis entails an extra step compared to
the peak calling analysis. In addition to the routine pre-processing steps, the reads in each window
of an input sample will be subtracted from its respective paired ChIP sample if they are matched.
In the case of uneven number of ChIP/input samples within each group or unpaired ChIP and input
samples, the mean input reads will be subtracted from each ChIP sample. Any negative resulting
values are redefined as zero counts. As mentioned earlier, the hypothesis will be tested both ways,
calling differential binding sites enriched in each group.
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2.2.3 Motif analysis
MEME (Bailey and Elkan, 1994) was used to identify over-represented motifs in the binding
sites. For TF datasets, peaks that were found in all programs were used, and the region within
150bp of the peak mode was used as input to MEME. The most significant motifs identified by
MEME are listed in Figure 2.1, and were consistent with previous reports (Han et al., 2013; Jothi
et al., 2008). Upon obtaining the motif position specific score matrix (PSSM) for each TF from
MEME, FIMO (Grant et al., 2011) was used to find motif matches in the regions within 150bp of
the peak mode found by each program to identify the motif occurrences in the peaks.
2.2.4 Unique peak analysis
The versions, parameters and significance cut-offs used for each program are provided in Table
2.2 and Appendix A. The unique peaks for each program were defined as the peaks not overlapping
any peak from the alternative program being compared. Since the number of unique peaks was
often highly imbalanced, we examined the same numbers of top unique peaks with a maximum
of 500. If too few unique peaks (less than 150) were identified, then the top 500 peaks identified
by each but with the highest difference in rank were used as a surrogate to unique peaks. The
heatmaps of unique peaks were generated using HOMER (Heinz et al., 2010), and visualized with
Java TreeView (Saldanha, 2004).
2.3 Results
2.3.1 Overview of the PePr method
A schematic overview of the PePr pipeline is shown in Figure 2.2. After shifting forward and
reverse strand reads to achieve proper alignment, PePr estimates a recommended window width
based on the median peak width among top pre-candidate peaks to optimize statistical power. This
is in contrast to most peak-finders, which use a fixed or user-specified window size. Motivated
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by the importance of modeling variation in RNA-Seq data, we model read counts with a negative
binomial distribution to account for extra-variation beyond that of the Poisson distribution observed
in replicated ChIP-seq data (Figure 2.3). Unlike the RNA-Seq methods, however, we estimate the
dispersion parameter ψ (which accounts for extra-variation) from the local genomic area. After
calculation of p-values, PePr merges adjacent significant windows to form continuous peak regions,
which then undergo multiple post-processing steps to generate the final peak calls.
The motivation for estimating ψ using local genomic information is that estimates of ψ from
one window are often unstable due to the small sample sizes commonly used in ChIP-seq studies.
This problem of unstable variance estimates in experiments with small sample size has been studied
extensively in the context of microarray data analysis, where using information from other genes
hasshown significant improvement (Sartor et al., 2006; Smyth, 2004). For ChIP-seq data, we
conjectured that close genomic regions share a similar microenvironment, and thus their behavior
across samples may be correlated. Especially for histone marks like H3K27me3, that result in
broad peaks, the estimated dispersion parameters from adjacent regions show strong correlation
(Figure 2.4). Given the high auto-correlation observed for ψ estimates along the genome, including
information from nearby windows effectively increases the sample size, improving the robustness
of the estimator.
2.3.2 Comparison to other methods
We assess the performance of PePr by applying it to eight TF ChIP-seq datasets: NRSF,
ATF4, CTCF, GABP, NRF1, SMC3, USF1 and USF2, and to a histone modification dataset: tri-
methylation of Histone 3 lysine 27 (H3K27me3). The performance was compared with MACS,
MACS2, SPP, ZINBA, edgeR and diffReps for TF data, and to SICER, ZINBA, edgeR, Diff-
Bind and diffReps for histone data. MACS and SICER are among the favorite choices for sharp
peaks and broad peaks respectively. ZINBA uses a similar sliding window approach, and is geared
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towards either sharp or broad peaks. MACS and ZINBA were run with both the Combine the
Replicates (CR) and Separate Analyses (SA) approaches described above. IDR was incorporated
with MACS2 and SPP, as is recommended by the ENCODE project. EdgeR was performed in two
ways in order to distinguish the effects of the core statistical model from the effects of the pre- and
post-processing steps: adopting all of PePr’s pre- and post-processing steps, and following a basic
processing procedure. We denote them as edgeR-plus and edgeR-basic, respectively, in the main
text.
Comparison of PePr and alternative methods using NRSF ChIP-seq data
The NRSF data consists of two ChIP and two input DNA samples, each sample having 14.3-
26.6 million mapped reads. PePr identified a total of 5,284 peaks, comparable to diffReps, edgeR,
SA and IDR-based approaches (Figure 2.5 B-F(i), Figure 2.6). CR-based approaches identified
significantly more peaks, as expected since they gained coverage by pooling samples in the same
group. This trend in number of peaks was also observed for the other TFs (Table 2.1). Comparing
the ranks of peaks among the methods, we observed high correlation between PePr and MACS-CR
(Pearson’s r = 0.73), MACS-SA (r = 0.79), SPP-IDR (r=0.93), MACS2-IDR (r= 0.65), edgeR-basic
(r=0.78), and edgeR-plus (r = 0.84), but much lower correlation between PePr and ZINBA-CR
(r=0.14), ZINBA-SA (r=0.16), and diffReps (r=-0.25) (Figure 2.7). This trend in rank correlations
between PePr and the other methods was also observed for the other TFs (see Figure 2.8 for ATF4).
The most direct assessment of peak-calling results that has been used is visual inspection of
the shape and read coverage of the peak regions (Landt et al., 2012; Rye et al., 2011), however
because this evaluation process cannot be fully automated, it is often overlooked in the evaluation
of ChIP-seq methods. Instead, much of the literature depends on motif occurrence rate as the
main performance measure, which can be inaccurate when the goal of the analysis is to identify
differential or consistent binding sites under a specific biological context. Thus, we present visual
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inspections of the peak profile results, as well as the motif occurrence rates in light of these results.
For each comparison between PePr and an alternative approach, we examined the peaks uniquely
found by each (see Methods). In most of the comparisons (except for comparing to diffReps),
PePr-unique peaks were more consistent between replicates and showed stronger read intensity
(Figure 2.5 A-E (iii) and Figure 2.6) than the alternative program. Examining each peak individ-
ually (Figure 2.5 A-F (ii)), PePr-unique peaks exhibited a smooth peak shape and a strand lag,
whereas unique peaks found by other approaches either had low read count which formed ambigu-
ous shapes (MACS-SA, ZINBA-SA and edgeR-plus), peak profile shapes suggesting inconsistent
binding (MACS-CR, ZINBA-CR, SPP-IDR and MACS2-IDR) or severe PCR-duplications (most
notably diffReps and edgeR-basic). As expected by the limitation of the CR approach (including
IDR), many of their unique peaks were only observed in one replicate (Figure 2.5 A,B(ii)).
In the average signal intensity plots, the mode height of MACS-CR, MACS2-IDR and diffReps
unique peaks were higher than PePr-unique peaks (Figure 2.5 A,B,F(iv)); however, they were not
the expected peak shape, but rather strongly spiked with width close to the read length. This
suggests that the reads forming these peaks were mostly PCR duplicates from a limited number of
sequences. Some diffReps-unique peaks even had the same peak shape in the control samples, but
with fewer reads (Figure 2.5 F(ii,iv)). Whereas the narrow spiked modes are likely false positives
with no shift size between strands, the signal levels of the shoulders of these plots likely represent
real binding sites, with the expected shift size between strands. The signal in these shoulder regions
are higher in PePr than the alternatives (Figure 2.5 A,B(iv)).
We compared the motif rates for peaks uniquely identified by PePr or an alternative approach
(Table 2.3). The peaks uniquely found by PePr had comparable motif occurrence rate to MACS-
CR, ZINBA-CR and MACS2-IDR, and had substantially higher motif occurrence rate than MACS-
SA, ZINBA-SA, SPP-IDR, diffReps and edgeR-basic (Table 2.3). However, the motif rate of
PePr’s unique peaks is lower than edgeR-plus for NRSF, contrary to their stronger read signals
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(Figure 2.5 E (iv)). The difference between edgeR-plus and edgeR-basic suggests that adopting
PePr’s processing steps results in a marked improvement. The CR approaches gained coverage
by pooling the samples, resulting in a motif occurrence rate similar to that of PePr. Although
the motif is often present, many of their unique peaks only showed enrichment in one replicate,
and thus would likely be false positives for identification of consistent binding sites in a specific
biological context under study. In the case of diffReps, the low motif occurrence rate in the unique
peaks suggests that those peaks with a narrow spiked shape were likely not true NRSF binding
sites.
Comparison of PePr and alternative methods using ATF4 and additional ENCODE ChIP-seq data
We repeated the comparison among methods on ATF4 ChIP-seq data, which had three samples
each of ChIP and control (each having 26.8-30.2 million mapped reads), and the control samples
were from chromatin immunoprecipitated ATF4 knock-out mice. All methods identified nearly
twice as many or more peaks for ATF4 as for NRSF, except diffReps, which identified substantially
fewer peaks than all other methods (Table 2.1). Again, we examined the unique peaks found by
PePr versus the other programs. In all comparisons, we observed PePr unique (or ranked higher)
peaks had higher read intensities (if we remove the high middle spike which is likely due to PCR
duplications) and higher motif occurrence rate than the alternative programs, including edgeR-plus
(Figure 2.9, Figure 2.10, and Table 2.3).
We analyzed six additional ENCODE TF datasets (CTCF, GABP, NRF1, SMC3, USF1 and
USF2), which had conserved motifs and both duplicated ChIP and control samples. Since we
showed in the NRSF comparison that the CR-based methods identify many sites that are incon-
sistent among samples, in these additional datasets we compared PePr to each of the alternative
methods that take into account variation/differences among the replicates: diffReps, edgeR-basic,
edgeR-plus, MACS-SA, and ZINBA-SA, with the same motif analysis (Table 2.4). In 24 of 30
40
comparisons, PePr-unique peaks had higher motif occurrence rate than the alternative method.
Comparison of PePr with alternative methods using a histone modification dataset
Oncogenic human papillomavirus (HPV) infection and tobacco-use are associated with the eti-
ology of two subtypes of oropharyngeal squamous cell carcinomas (SCCs) (Chung and Gillison,
2009). We generated H3K27me3 ChIP-seq data from two HPV(+) and two age and gender matched
HPV(-) SCC cell lines. The aim of the study was to identify candidate differential H3K27me3
sites by HPV status. The H3K27me3 mark exhibits very broadly enriched regions in ChIP-seq
data, which we observed to be often highly variable between samples (Figure 2.11). Due to the
high variation among samples and the goal of identifying consistent differences between HPV(+)
and HPV(-) tumors, the CR approach would not be suitable; thus, we compared PePr to the SA ap-
proach using two peak-callers developed for broad peaks: ZINBA and SICER, as well as diffReps,
DiffBind and edgeR-plus.
To find HPV(-) specific peaks, we used HPV(-) cell lines as the test samples, and compared
them to the HPV(+) cell lines. For ZINBA and SICER, age and gender matched samples were
used in each pair. SICER identified 35403 HPV(-) specific peaks for the first pair, 20207 peaks
for the second pair, and 8823 regions (19%) were found in both. ZINBA identified 13814 peaks
and 22701 peaks respectively, and only 1878 regions (5%) were found in both, illustrating the
substantial level of variation among the samples in each group. PePr, diffReps, and edgeR-plus
identified 1015, 17924 and 181 peaks, respectively. EdgeR-plus identified very few significant
peaks, possibly due to the high global dispersion parameter estimated from the data, whereas PePr
estimated it locally. DiffReps was much more sensitive than edgeR as previously shown for broad
peaks (Shen, et al., 2013). For DiffBind, SICER peaksets were generated for each cell line and
used as input to the program. The peaksets were merged and a total of 29510 regions were tested.
DiffBind has two built-in analysis methods: edgeR and DESeq. DiffBind with edgeR reported no
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significant peaks (possibly due to the same reason explained above). With DESeq it identified 918
HPV(-) specific sites, which we use for DiffBind below.
Since the number of peaks varied substantially among the programs tested, we evaluated how
each program prioritized the peak findings. The top 900 peaks from each program were chosen
based on their significance and compared (edgeR-plus was excluded due to finding so few peaks;
900 was chosen because all other methods identified 900 sites). Figure 2.13A shows the overlap
between PePr and each of the other five programs. We examined the top ranking peaks that were
uniquely identified by PePr, SICER, ZINBA, DiffBind or diffReps. The peaks uniquely identified
by PePr were consistent between replicates, while the peaks uniquely found by SICER, ZINBA, or
DiffBind often showed large differences in coverage between samples in the same group (Figure
2.13 B,C, D). DiffReps unique peaks seemed consistent in coverage between samples in the same
group, however, the ratio in coverage between the test and control groups was smaller than that
of PePr (Figure 2.13 E). In addition, when looking at each peak individually, the top diffReps
unique peaks had average peak width less than 2 kb, which is much narrower than that expected
for H3K27me3.
To further assess the robustness of the peak-calling methods (as opposed to differential binding
methods) in identifying broad peaks, we conducted a scaling FDR analysis as described in (Zang
et al., 2009) for all four ChIP-seq versus four matching input controls. Briefly, for each replicate,
we randomly sample half of the reads to produce several pseudo half-size libraries. The proportion
of peaks called only in the half-size library but not in the full-size library is defined as the scaling
FDR. Performing this for ten simulations, we observed that PePr had a smaller scaling FDR (mean
= 1.66%) than SICER (mean = 4.56%), ZINBA (mean = 11.38%), diffReps (mean=12.54%) and
edgeR-plus (mean=5.83%), and thus PePr’s peak prediction was most robust to differences in
coverage levels (Figure 2.12).
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2.4 Discussion
Currently, there is a lack of ChIP-seq analysis programs that account for biological variability
within the peak-finding process. We have developed a method and tool, PePr, which uses a local
negative binomial model to identify consistent or differential binding sites among ChIP-seq data,
and that additionally estimates the optimal moving window size and offers post-processing steps
to reduce false positives and refine peak resolution.
Variation among samples in ChIP-seq data can sometimes be quite large, such that some bind-
ing sites, even for transcription factors, are not reproducible (Landt et al., 2012). Inconsistent TF
peaks among biological samples can exist for many reasons, including differences in accessibility
of chromatin regions (e.g., due to histone tail modifications or DNA methylation), common se-
quence variants, competitive or cooperative binding differences with another TF (Whitfield et al.,
2012), or technical artifacts that only occurred in one of the replicates. However, all but the last of
these reasons are not significant concerns for most peak-finder programs, the goal of which is to
identify all potential binding sites rather than consistent or differential binding sites. In addition,
as public datasets from large consortiums such as ENCODE (Consortium, 2012) more comprehen-
sively cover known TF binding in commonly used cell and tissue types, there will be less incentive
for individual laboratories to identify all of the potential binding sites for a protein, as many will be
available. A more refined hypothesis may be “where does this TF (or histone modification) bind
consistently in this specific context (a specific disease, developmental stage, exposure, or treat-
ment)?” Accurately modeling the variation is highly important in population epigenomics studies
where substantial variation exists among samples, not only among individuals but also between
tissue types (Cui, et al., 2009), developmental time points (Rugg-Gunn, et al., 2010; Sarmento, et
al., 2004), and during disease progression (Conte and Altucci, 2014; Jakopovic et al., 2013).
We compared PePr to five commonly used single-sample peak-finders that use different under-
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lying statistical models (MACS, MACS2, SPP, ZINBA, and SICER), as well as three programs
that were designed for replicates (diffReps, DiffBind and edgeR), and found that PePr performed
favorably in terms of consistently enriched read counts, motif occurrence rate and known charac-
teristics of TF binding based on visual inspection. For comparison with MACS, ZINBA or SICER,
we either performed separate paired analyses and then called peaks in the overlapping regions (SA)
or combined the reads for the replicates and called peaks from the concatenated lists (CR). IDR
was incorporated with MACS2 and SPP to determine the peak list cut-off, as recommended by the
ENCODE consortium. Visual inspection of the peak shape and summarizing the read counts in
peaks were extremely valuable in characterizing the unique tendencies of each approach. In par-
ticular, MACS was sensitive to detecting regions that had very low background and tended to miss
peaks that had a relatively high background (Figure 2.5A(iii)); visual inspection of the ZINBA
and diffReps unique peaks revealed that many had similar peak shape in both ChIP and control
samples; SPP had severe false negatives for the NRSF data, which is possibly due to the removal
of true binding sites that SPP mistakenly assumed to be artifacts due to having unexpectedly small
shift size (i.e., in the “phantom peak” as defined in (Landt et al., 2012)). When we compared PePr
to SPP-IDR and MACS2-IDR, we observed PePr-unique peaks (that are missed by the other two)
had high read counts and motif rate.
Although motif occurrence rate is a useful marker for DNA binding, its value as a marker
for consistent or differential DNA binding is not as clear. For identification of all DNA binding
sites, motif analysis is expected to be specific (if the motif is found within a peak, it is assumed
that binding occurs) but not necessarily highly sensitive (indirect binding cooperatively with other
protein(s) may not result in a motif occurrence). Because the percent of binding sites without
a motif is only expected to vary by DNA binding protein, and not by peak-caller, this is often
ignored when comparing peak-callers. However, for consistent or differential binding experiments
we can no longer assume specificity; a peak-finder that identifies fewer overall peaks with a motif
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than an alternative may be correct in not calling the additional peaks as consistently bound or
differentially bound. Given these caveats, we nonetheless found motif occurrence rate informative
for interpreting our results when used in conjunction with visual inspection of peaks. The large
improvement in motif occurrence rates for PePr-unique peaks compared to peaks identified by
the Separate Analyses (SA) approaches and edgeR-basic suggests that peaks with higher read
intensities and the expected smooth peak shape are more likely to contain a motif (Table 2.3). The
CR approaches, on the other hand, were comparable in motif occurrence rate to PePr, but many of
these were only bound in one replicate upon visual inspection, and thus are likely false positives
for identification of consistent binding sites in the biological system under study.
Although PePr and edgeR use a similar underlying negative binomial model, edgeR lacks initial
steps required for ChIP-seq peak finding (shifting opposite strand reads, defining and summarizing
reads per window, etc), does not incorporate information from neighboring windows which espe-
cially benefits histone modification analyses, and does not offer post-processing steps to improve
peak resolution or reduce false positives. In 5 of the 8 TF datasets, PePr performed better in mo-
tif rate than edgeR if the same PePr-processing steps are performed for edgeR; with the histone
data, PePr was more sensitive than edgeR due to estimation of the dispersion parameters locally.
PePr’s post-processing steps improved edgeR’s performance when there is a high proportion of
PCR-duplicate peaks (6% in NRSF, 1.6% in ATF4, and <0.5% in other datasets). DiffBind was
previously shown to work well with differential binding in TF data (Ross-Innes, et al., 2012), how-
ever, in H3K27me3 data with broad and highly variable peaks, DiffBind’s edgeR module had very
low detection power, while its DESeq module identified 918 peaks, many of which were inconsis-
tent among samples. DiffReps resulted in unpredictable numbers of peaks across the datasets we
tested, for example, it identified substantially fewer peaks than all other programs for ATF4 and
SMC3 (Table 2.1), but many more for H3K27me3.
Due to the lack of benchmarks in histone modification datasets, in this dissertation we mainly
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relied on transcription factor datasets to compare methods. However, PePr is adaptable to datasets
with either sharp or broad peaks due to its empirical estimation of the optimal sliding window size,
and thus is equally relevant for analysis of histone modification ChIP-seq datasets as illustrated
with our H3K27me3 data. H3K27me3 tends to occur in broad regions several kilobases in length,
making consistent peak calling more difficult. Based on our visual inspection of peaks and scal-
ing FDR analysis for the approaches compared, we showed that PePr identified binding regions
consistent between groups without being sensitive to changes in read coverage.
One limitation of PePr is that it currently does not perform paired analysis, similar to the
limitation of multiple RNA-Seq differential analysis programs (Anders and Huber, 2010; Trapnell
et al., 2013); thus, for example, the paired nature of tumor and patient-matched normal samples,
could not be taken into account. For experiments requiring covariates, we currently recommend
edgeR. PePr also makes the assumption that the quality of data for each ChIP-seq experiment is
approximately equal, similar to most methods for other types of high-throughput analysis. When
this assumption is violated, the result may be a high false negative rate due to missing peak regions
in the lower quality sample(s); this may especially be true for experiments with very small sample
size. In this case, users may obtain better performance using a different peak finder on individual
samples, and a secondary method to explore options to combine results. Future versions of peak-
finders for replicated ChIP-seq data could take into account quality, for example by assigning a
weight to each sample.
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Figures
Figure 2.1: Motif logos for all TFs used in our comparisons. (A) Motif logo identified by
MEME for NRSF data. NRSF binding sites have variable spacing between the two halves of the
motif. (B-H) Motif logo identified by MEME for ATF4 (B), CTCF (C), GABP (D), NRF1 (E),
SMC3 (F), USF1 (G) and USF2 (H).
47
Figure 2.2: Workflow of PePr
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Figure 2.3: Extra-variance beyond that of the Poisson distribution is observed in ChIP-seq
data. Plot of mean versus variance estimates for windows across the genome in (A) NRSF ChIP-
seq data with two replicates (window size of 200bp), (B) ATF4 ChIP-seq data with three biological
replicates (window size of 160bp), and (C) H3K27me3 ChIP-seq data from squamous cell carci-
noma cell lines, with four replicates (window size of 340bp). The red line indicates the expected fit
based on the Poisson distribution. The blue line is the fitted curve estimated using cubic smoothing
spline.
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Figure 2.4: H3K27me3 data show a high autocorrelation of the dispersion parameters es-
timated for nearby windows. The genome was split into non-overlapping windows of 336 bp
(Optimal window size estimated by PePr) and the dispersion parameter for each window was
estimated. The autocorrelation of the dispersion parameters of the windows separated by (i-1)
windows showed a correlation coefficient greater than 0.4 for to the range of 10 - 20 windows
apart.
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Figure 2.5: Comparison of PePr to other approaches on NRSF data. Other approaches are:
MACS-CR (A); MACS2-IDR (B); SPP-IDR (C); MACS-SA (D); edgeR-plus (E); diffReps (F).
The subplots in each panel are: (i) Venn diagram of overlap between peaks found by PePr and the
alternative approach. (ii) Representative genomic view of the unique peaks. Each line represents
one of the replicates in the group, with the top window being the test group and the bottom window
being the control group. (iii) Heatmaps showing the signal intensity of the test group across the
unique peaks. The x-axis denotes the relative chromosomal locations centered at the peak mode;
each row denotes one peak. (iv) Average signal intensity of the unique peaks. Solid lines represent
the test group, while dashed lines represent the control group. ZINBA and edgeR-basic results are
presented in Figure S4.
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Figure 2.6: Comparison of PePr to ZINBA-CR (A) ZINBA-SA (B) and edgeR-basic (C) on
NRSF data. (i) Venn diagram of overlap between peaks found by PePr and the alternative ap-
proach. (ii) Representative genomic view of the unique peaks. Each line represents one of the
replicates in the group, with the top window being the test group and the bottom window being
the control group. (iii) Heatmaps showing the signal intensity of the test group across the unique
peaks. The x-axis denotes the relative chromosomal locations centered at the peak mode; each row
denotes one peak. (iv) Average signal intensity of the unique peaks. Solid lines represent the test
group, while dashed lines represent the control group.
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Figure 2.7: Rank comparisons between PePr and the alternative approaches on NRSF
data. Rank comparisons between PePr and (A) MACS-CR (Pearson’s r=0.73), (B) MACS2-IDR
(r=0.65), (C) SPP-IDR (r=0.93), (D) MACS-SA (r=0.79), (E) edgeR-plus (r=0.84), (F) diffReps
(r=-0.25), (G) ZINBA-CR (r=0.14), (H) ZINBA-SA (r=0.16), and (I) edgeR-basic (r=0.78). The
peaks are ranked by the significance for each program. The points located at the top of each plot are
PePr-unique peaks, and the points on the right margin of each plot are unique peaks for the alter-
native approach. Red and orange points refer to subsets of PePr-unique and alternative-approach-
unique peaks which were used in the enrichment signal and motif occurrence comparisons.
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Figure 2.8: Rank comparisons between PePr and the alternative approaches on ATF4
data. Rank comparisons between PePr and (A) MACS-CR (Perason’s r=0.82), (B) MACS2-IDR
(r=0.82), (C) SPP-IDR (r=0.90), (D) MACS-SA (r=0.86), (E) edgeR-plus (r=0.51), (F) diffReps
(r=-0.14), (G) ZINBA-CR (r=0.28), (H) ZINBA-SA (r=0.68), and (I) edgeR-basic (r=0.56). The
peaks are ranked by the significance for each program. The points located at the top of each plot are
PePr-unique peaks, and the points on the right margin of each plot are unique peaks for the alter-
native approach. Red and orange points refer to subsets of PePr-unique and alternative-approach-
unique peaks which were used in the enrichment signal and motif occurrence comparisons.
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Figure 2.9: Comparison of PePr to other approaches on ATF4 data. Other approaches are:
MACS-CR (A); MACS2-IDR (B); SPP-IDR (C); MACS-SA (D); edgeR-plus (E); diffReps (F).
The subplots in each panel are: (i) Venn diagram of overlap between peaks found by PePr and the
alternative approach. (ii) Representative genomic view of the unique peaks. Each line represents
one of the replicates in the group, with the top window being the test group and the bottom window
being the control group. (iii) Heatmaps showing the signal intensity of the test group across the
unique peaks. The x-axis denotes the relative chromosomal locations centered at the peak mode;
each row denotes one peak. (iv) Average signal intensity of the unique peaks. Solid lines represent
the test group, while dashed lines represent the control group. ZINBA and edgeR-basic results are
presented in Figure S9.
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Figure 2.10: Comparison of PePr to ZINBA-CR (A), ZINBA-SA (B) and edgeR-basic (C)
on ATF4 data. (i) Venn diagram of overlap between peaks found by PePr and the alternative
approach. (ii) Representative genomic view of the unique peaks. Each line represents one of the
replicates in the group, with the top window being the test group and the bottom window being
the control group. (iii) Heatmaps showing the signal intensity of the test group across the unique
peaks. The x-axis denotes the relative chromosomal locations centered at the peak mode; each row
denotes one peak. (iv) Average signal intensity of the unique peaks. Solid lines represent the test
group, while dashed lines represent the control group.
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Figure 2.11: Example of an H3K27me3 enriched region showing high variation of ChIP-seq
signals across samples. Each profile represents one ChIP-seq sample, with the x-axis and y-axis
denoting chromosomal location and read coverage respectively.
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Figure 2.12: A scaling FDR analysis of the H3k27me3 dataset shows PePr was most robust
to differences in read coverage level. The scaling FDR was calculated for PePr, ZINBA, SICER,
diffReps, and edgeR on the H3K27me3 data as described in the main text. PePr had the lowest
scaling FDR estimate of the methods tested.
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Figure 2.13: Comparison of PePr to other approaches for H3K27me3 data. (A) Venn diagrams
showing the overlap between the top 900 peaks from PePr and alternative approaches (the number
in parenthesis shows the number of peaks in the alternative program that overlap with PePr peaks).
(B, C, D, E) Each plot on top shows the genomic view of top ranking peaks uniquely found by
PePr or the alternative approach. The bottom plots show the normalized coverage of reads in
unique peaks, sorted by the average coverage of both HPV(-) samples.
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Tables
Table 2.1: Total number of peaks identified in each TF dataset.
NRSF ATF4 CTCF GABP NRF1 SMC3 USF1 USF2
PePr 5,284 15,338 34,548 5,158 4,729 25,789 6,837 5,025
MACS-CR 15,068 39,774 50,286 5,920 13,052 48,945 36,517 26,755
ZINBA-CR 9,468 25,684 57,398 5,880 14,052 62,044 12,343 23,376
MACS-SA 4,495 10,592 38,576 3,122 5,344 15,861 5,777 7,476
ZINBA-SA 5,374 11,453 41,675 4,613 6,286 21,912 5,706 9,060
MACS2-IDR 4,946 9,337 35,033 3,991 5,584 23,274 6,364 6,078
SPP-IDR 4,861 12,160 40,006 5,095 5,042 25,470 7,074 6,794
diffReps 6,030 5,781 29,317 3,992 3,474 3,499 4,270 3,642
edgeR-basic 6,790 14,463 43,443 6,962 6,643 15,731 7,581 16,397
edgeR-plus 7,868 14,057 40,841 8,116 9,667 13,303 7,315 12,426
Table 2.2: Significance cut-offs for ChIP-seq programs involved. *see program parameters for
details.
Program Significance cuttoff
PePr p-value <1e-5
MACS p-value <1e-5
ZINBA Posterior Probability >0.95
SICER FDR <1e-2
MACS2-IDR *optimum set
SPP-IDR *optimum set
edgeR p-value <1e-4
diffReps p-value <1e-4
DiffBind FDR <0.1
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Table 2.3: Motif occurrence rate in unique peaks called by PePr or alternative programs for
NRSF and ATF4.*peaks with highest rank difference were used, as explained in Methods.
NRSF ATF4
Program compared
%motif %motif
# peaks PePr alternative # peaks PePr alternative
MACS-CR 227 77.1 83.2 152 48.0 26.3
ZINBA-CR 500* 97.8 92.6 500* 67.0 51.4
MACS2-IDR 416 76.2 78.6 211 40.3 20.0
SPP-IDR 500 95.2 66.4 500 43.0 39.2
MACS-SA 500 89.0 70.4 500 45.8 29.8
ZINBA-SA 499 76.5 63.9 332 56.0 16.9
edgeR-basic 366 74.8 67.5 500 56.2 39.4
edgeR-plus 151 67.5 82.7 500 59.0 45.8
diffReps 403 79.9 25.6 500* 75.2 61.6
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CHAPTER III
Subtypes of HPV-positive head and neck cancers are associated
with HPV characteristics, copy number alterations, PIK3CA
mutation, and pathway signatures
3.1 Introduction
Head and neck cancer (HNC) is the 6th most prevalent non-skin cancer in the world, affecting
approximately 600,000 patients per year, and with five-year survival rates ranging from 37 to 62
percent(Ferlay et al., 2010; Vokes et al., 1993). The majority of HNC cases have been historically
attributed to excessive exposure of carcinogens such as tobacco and alcohol, but a significant and
increasing proportion of cases are associated with high-risk human papillomavirus (HPV) infec-
tion, with HPV type 16 being the most common, accounting for 87% of HPV(+) cases in oropha-
ryngeal HNC, 68% in oral HNC and 69% in laryngeal HNC carcinomas (Kreimer et al., 2005).
Currently, approximately 75% of oropharyngeal tumors are associated with HPV; the HPV preva-
lence is relatively rare but still occurs in non-oropharyngeal sites such as oral cavity and larynx
(Ang et al., 2010; Chung et al., 2014). Overall, HPV(+) HNC patients tend to have more favor-
able prognosis and treatment response rates, and different patient characteristics such as younger
age at diagnosis, lower smoking rate, and higher intake of beneficial micronutrients compared to
The work in Chapter III will be submitted as Zhang Y, Koneva LA, Virani S, Arthur AE, Virani A, Hall PB,
Warden CD, Carey TE, Chepeha DB, McHugh JB, Wolf GT, Rozek LS, Sartor MA. “Subtypes of HPV-positive head
and neck cancers are associated with HPV characteristics, copy number alterations, PIK3CA mutation, and pathway
signatures.”
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their HPV(-) counterparts (Arthur et al., 2011; Dayyani et al., 2010; Duray et al., 2014). They
also have key molecular differences, such as the observed high expression of p16 (CDKN2A) in
HPV(+) tumors and loss of p16 expression in HPV(-) tumors, and HPV(+) tumors are generally
less-differentiated (Syrjanen, 2010) and have different copy number profiles (Hayes et al., 2015)
than HPV(-) tumors.
HPV normally infects the basal layer of the epithelium, and then exploits the epithelial-to-
keratinocyte proliferation and differentiation pathways in order to complete the viral life cycle.
HPV expresses two main viral oncoproteins, E6 and E7, which cooperatively inhibit apoptosis
and enhance tumor cell growth and proliferation by inducing degradation of tumor suppressor
p53 and disruption of function of Rb, respectively (Moody and Laimins, 2010). Alteration of
additional pathways, such as suppression of immune response (Tindle, 2002) and cell adhesion
(Whiteside et al., 2008), induction of DNA damage(Duensing and Mu¨nger, 2002), centrosome
amplification(Duensing et al., 2000) and oxidative stress (Williams et al., 2014), may also be im-
portant for tumor transformation.
High-risk HPV E6 is expressed in cells at two main isoforms: a full-length variant (E6) and
a few truncated variants often collectively referred to as E6*. It was shown that E6* inversely
regulate the ability of E6 to degrade p53 (Pim and Banks, 1999). Full-length E6 and E6* also
bind to different sites of procaspase 8 and alternatively modulate its stability (destabilizing and
stabilizing, respectively) (Tungteakkhun et al., 2009). Altogether, these studies suggests that E6*
has distinct functions from full-length E6. In addition to the combined oncogenic potential of HPV
E6 and E7, the integration of part or all of the HPV genome into the host genome is suggested to
be a driver of the neoplastic process, and is estimated to occur in 75% of HNC cases, of which
54% are integrated into a known gene (Parfenov et al., 2014). Integrated viral transcripts are
more stable than those derived from episomal HPV (Jeon et al., 1995), and integration confers
an increased proliferative capacity and selective growth advantage (Jeon et al., 1995; Moody and
70
Laimins, 2010). Expression of these transcripts is key, as it has been observed that tumors positive
for HPV DNA, but negative for HPV RNA, are similar to HPV(-) tumors with respect to gene
expression and TP53 mutation frequencies (Wichmann et al., 2015).
HPV(+) HNC tumors represent a different molecular entity to HPV(-) tumors, distinct in their
disease etiology and response to treatment. Several studies have investigated the differences in
gene expression and copy number changes between HPV(+) and HPV(-) tumors (Pyeon et al.,
2007; Slebos, 2006), or have defined expression subtypes irrespective of HPV status (Chung et al.,
2004; The Cancer Genome Atlas Network, 2015). However, in most genome-wide studies, the
number of HPV(+) cases are relatively low, therefore obscuring the discovery of subtypes within
the HPV(+) population. In one study, Pyeon et al found two distinct subgroups of HPV(+) cancers,
which were differentiated by a few key genes (Pyeon et al., 2007). Keck et al also independently
identified two HPV(+) subtypes (Keck et al., 2015), and characterized differences in morphol-
ogy (differentiation and proliferation), expression (mesenchymal and immune response) and copy
number of a few key neoplasm genes (PIK3CA, TP63, SOX2) between subtypes. However, both
studies used microarray data, thus limiting their ability to comprehensively characterize the differ-
ences between subtypes and identify the underlying causes of the expression differences.
Here, by deep analyses of 36 HNC tumors (18 HPV(+); 18 HPV(-)) collected at the University
of Michigan with transcriptome and whole genome copy number alterations (CNA) data, we define
two robust HPV(+) subtypes distinguished by gene expression patterns. The two clusters correlate
with genic viral integration status, E2/E4/E5 expression and E6 splicing ratio. In addition, the
clusters show different CNA patterns, mutation frequencies in PIK3CA and expression of cancer-
relevant pathways, such as host immune response and keratinocyte differentiation. Similar analysis
carried out on 66 additional HPV(+) samples from The Cancer Genome Atlas (TCGA) yielded the
same findings, demonstrating the robustness of the subtypes and their related characteristics.
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3.2 Methods
3.2.1 Tumor tissue acquisition, DNA and RNA extraction.
As a part of our ongoing survivorship cohort, we identified incident cases of HNC patients
at University of Michigan hospital with untreated oropharynx or oral cavity squamous cell carci-
noma between 2011 2013 were screened for eligibility. Written informed consent was obtained.
The study was approved by the University of Michigan Institutional Review Board. Pretreatment
Tumor tissue and blood were collected into a cryogenic storage tube and flash frozen in liquid
nitrogen by surgical staff until storage at -80C. The flash frozen tissues were embedded in OCT
media in vinyl cryomolds on dry ice and stored in -80C until prepared for histology. H&E slides
were sectioned from each frozen tumor specimen on a cryostat and assessed by a board certified
pathologist for degrees of cellularity and necrosis. Criteria used for inclusion in the study were a
minimum of 70% cellularity and less than 10% necrosis. The first 36 tumors meeting these criteria
were selected. Using a sterile scalpel, surface scrapings were taken directly from the frozen tissue
blocks from the region of tissue identified as having at least 70% tumor cellularity, over dry ice to
allow the tissue to remain frozen. Frozen scrapings were placed into pre-chilled tubes on dry ice
and processed using the Qiagen AllPrep DNA/RNA/Protein Mini Kit (Valencia, CA, USA) as per
manufacturer protocol. Blood DNA from the same patients was isolated using the Qiagen QIAamp
Blood DNA Mini Kit.
3.2.2 RNA-seq and SNP-array protocol
RNA library construction and sequencing on Illumina HiSeq using 100 nt paired-end reads
were performed by the University of Michigan DNA sequencing Core Facility. Samples were mul-
tiplexed to avoid lane variations. DNA from all tumors and matched blood samples was run on the
Ilumina HumanOmniExpress BeadChip SNP-array. The raw microarray images were processed
by Illumina Genome Studio to yield the log R ratio (LRR) values and B allele frequency (BAF)
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values. Raw and processed RNA-seq and SNP-array data can be accessed from GEO with the
accession number GSE74956.
3.2.3 RNA-seq analysis of the host gene expression
The RNA-seq library sizes ranged from 33 to 78 million reads (average of 47 million). The
raw sequences were aligned to hg19 using Tophat2 v2.0.11 (Kim et al., 2013) with default param-
eters, resulting in an alignment rate of 48%-92% (average 86%). Quality control was performed
using FastQC (Andrews, 2010) and RSeQC (Wang et al., 2012) before and after alignment. Gene
expression levels were quantified using HTSeq v0.6.1p1 with the ‘interFsection-strict’ option (An-
ders et al., 2014). Genes expressed at least 1 count per million (CPM) in at least 10% of the sam-
ples were kept for downstream analysis. Normalization and differential expression testing were
performed using the Bioconductor package edgeR v3.8.5 (edgeR-robust) (Robinson et al., 2010;
Zhou et al., 2014), and adjustments for multiple testing were made using the False Discovery Rate
approach.
3.2.4 Measuring HPV gene expression, and detection of HPV subtypes and genic integration
The libraries were also aligned to HPV genomes (downloaded from NCBI) using rnaSTAR
v2.3.0 (Dobin et al., 2013) to allow gapped alignment over splicing junctions. We aligned to the
HPV genomes of all high-risk types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
STAR first-pass alignment detected the most abundant splice junctions, which were then used in
the second-pass alignment. All of the quantification and analyses below were based on the second-
pass alignment. Samples were classified as HPV(+) if they had more than 500 read pairs aligned
to any HPV genome, and HPV type was determined as the type which had the most reads aligned.
No samples had between 50 and 1000 reads aligned to HPV, resulting in a very clear separation
between HPV positive and HPV negative. Overall we identified 14 HPV type16, one type18, one
type33, and two type35. Virus integration events resulting in HPV-host fusion transcripts were
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identified using VirusSeq (Chen et al., 2013b) with the default parameters. A positive integration
event was defined as having at least four discordant read pairs and at least one junction spanning
read. A tumor sample was called genic integration positive if it contained at least one identified
integration event.
HPV is a small genome with short oncogenes, therefore in order to optimize the comparability
between UM data and TCGA data in terms of HPV gene expression and splicing, all UM libraries
were trimmed to the first 48 base pairs (as 48bp was the length of the TCGA RNA-seq reads) for the
alignment to HPV genomes. This was implemented after observing differences between cohorts
when not trimming UM sample reads; the trimming removed these artefactual differences. HPV
gene expression levels were represented in the form of “count per million (CPM) value”, which
were calculated as the number of read pairs aligned to the HPV genome and intersected with each
gene, and then divided by the total library size and multiplied by one million.
3.2.5 Computing full-length E6 percentages
E6 is expressed in two main forms: (1) a full-length E6 isoform and (2) various spliced isoforms
of E6, collectively referred to as E6*. We define full-length E6 percentage as the ratio of full-
length E6 and all E6 transcripts. Because all E6* skip the first intron, we can compute full-length
E6 percentage as the ratio of the average coverage level in the first intron (approximate full-length
E6 level) divided by the average coverage level in the first exon (approximate all E6 transcript
level). We used rnaSTAR to identify the first introns for E6*, which are, in the format of [donor-
acceptor], [227-408], [234-415], [232-508] and [233-414] for type16, 18, 33 and 35, accordingly.
The average coverage of read pairs within the intron (i.e. 227-408 for HPV-16) was then divided
by the average coverage of read pairs within exon1 (i.e. 82-227 for HPV-16), where coverage was
computed by dividing the number of reads by the feature width (Fig 3.8D).
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3.2.6 Finding unique pathways in each HPV(+) cluster
To understand how the pathways were dysregulated in the context of all UM HNC tumors, we
ran edgeR and LRpath to find uniquely up- or down-regulated gene sets in each cluster (non-HPV,
HPV-KRT and HPV-IMU). To do this, we constructed a model matrix for edgeR with three group
labels: non-HPV, HPV-KRT and HPV-IMU. And then we ran edgeR GLM with the contrast matrix
(HPV-KRT vs non-HPV + HPV-IMU) to find genes uniquely up- or down-regulated in HPV-KRT
(the same step is repeated on HPV-IMU). Finally, we ran LR-path directional test to find enriched
pathways.
3.2.7 Unsupervised clustering of gene expression values
Standard hierarchical clustering was performed on the median-centered log-transformed count
per million (log-cpm) values. Genes used for clustering were chosen based on the following pro-
cedure. First, we calculated the rank of the variance and the rank of mean log-cpm for each gene
analyzed. Then we used the rank difference between variance and mean to sort the gene list. Genes
with a higher rank of variance than rank of the mean were considered more variable. Different
thresholds (top 5000 genes to all genes) were used to choose the gene list, but the clusters were ro-
bust to these differences, with at most one sample switching clusters. In addition, different distance
measures (Euclidean distance, centered and uncentered correlation), linkages (complete, average
and single) were also tested; again, the clusters were robust to the different parameters used. We
also performed consensus clustering (Monti et al., 2003) using recommended parameters provided
in the user manual, which produced the same clustering results. The final clusters reported were
using genes with a positive rank difference (6922 genes), uncentered Pearson’s correlation and av-
erage linkage. The same clustering method was performed on UM+TCGA HPV(+) samples, using
genes with a positive rank difference (6780 genes), uncentered Perason’s correlation and average
linkage. The consensus clustering results are presented in Fig 3.6A,B.
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3.2.8 Pathway scores
Sample-wise pathway scores were calculated for four selected representative gene sets: E6 reg-
ulated genes, EMT genes, T-cell activation (GO: 0042110) and keratinocyte differentiation (GO:
0030216). E6 regulated genes were derived from table 1 in Duffy et al (Duffy et al., 2003). EMT
genes were cancer EMT markers defined in table 1 in Zeisberg et al (Zeisberg and Neilson, 2009).
First, for each gene in the pathway, we ranked the samples according to their expression levels.
For each sample, the ranks of the genes were summed, and the resulting values are then centered
by mean and scaled by standard deviation across samples to give the final scores. For E6 nega-
tively regulated genes, we ranked the expression levels in descending order, because the direction
of regulation is known to be opposite.
3.2.9 RNA-seq mutation calling
Pre-processing and variant calling were performed following GATK Best Practices for RNA-
seq data (DePristo et al., 2011) for identification of single nucleotide polymorphisms (SNPs) and
small indels. Briefly, paired-end reads were aligned to the human genome using STAR v2.3.0
(Dobin et al., 2013). GATK v3.2-2 was used for indel realignment and base recalibration. Variants
were called for each sample using HaplotypeCaller. Variants which fell under any of the following
criteria were filtered out: quality scores less than 25 (QUAL<25), strong strand bias (FS >30),
normalized quality score (QD <2.0), or variants part of a SNP cluster (defined as 2 SNPs within
35 bps) indicating a false positive. Resulting variants were filtered by SnpEff v4.0e (DePristo
et al., 2011) to retain variants predicted to disrupt the primary structure of the protein. Rare and
damaging variants were identified using ANNOVAR (version released Nov12, 2014) (Wang et al.,
2010). Rare variants were defined as variants that are present in less than 5% of 1000 Genomes
(The 1000 Genome Project Consortium, 2012) and NHLBI Exome Sequencing Project subjects
(Fu et al., 2012). Damaging variants were those predicted to be damaging by either PolyPhen-2
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(Adzhubei et al., 2010) or SIFT (Pauline C. Ng and Steven Henikoff, 2003), stored in the ljb23
database. RNA-seq variant calling has the limitation that it can only uncover expressed mutations
that is greater than a certain coverage. For PIK3CA showcased in the main text, all of the samples
had an average coverage level that satisfied the minimum requirement (8X) to call variants. A
gene is denoted as mutated if it contains at least one predicted damaging mutation. Gene mutation
percent in a group is defined as the percent of samples containing mutated copies. The mutation
percent is calculated for each subtype (HPV-KRT and HPV-IMU) in each cohort (UM and TCGA)
separately.
3.2.10 TCGA RNA-seq analysis
RNA-seq fastq files of 66 TCGA HPV+ tumor samples were downloaded from cghub (Wilks
et al., 2014). The data were re-aligned and analyzed in the same way as UM RNA-seq data de-
scribed above, except for variant calling. Gene somatic mutations for TCGA samples were instead
downloaded from Xena (Goldman et al., 2015).
3.2.11 CNA analysis
OncoSNP v2.1 was run on every tumor and matched normal, with the setting that the maximal
possible stromal contamination is 0.5 (Yau et al., 2010). The level 1 through level 5 CNA output
data from OncoSNP were overlayed to provide the final CNA calls. The copy number for each
gene was calculated as the average of copy number of the segments overlapping the gene rounded
to the nearest integer. CNA data for TCGA samples were downloaded from TCGA data portal.
3.3 Results
3.3.1 Overview of differential expression results from HPV(+) and HPV(-) tumors
We performed transcriptomic analysis via RNA-deep sequencing on 36 tumor samples (18
HPV+ and 18 HPV-) to define gene expression levels. Supervised differential expression analysis
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using HPV status as the group variable identified 1887 and 1644 genes significantly up-regulated
and down-regulated in HPV(+) samples, respectively (FDR<0.05 and fold change>2). We anno-
tated the genes to neoplasm-related terms downloaded from Gene2Mesh (Ade, AS; Wright, ZC;
States, 2007), and reidentified several important differentially expressed genes: TP53, CDKN2A,
BRCA2, CYP2E1, KIT and EZH2 were significantly up-regulated in HPV(+) tumors, and CCND1,
GSTM1, HIF1A, MMP2, CD44 and MET were down-regulated. We performed Gene Ontology
enrichment analysis with LRpath (Sartor et al., 2009) and found that “immune response”, “cell cy-
cle”, and “DNA replication” were up-regulated in HPV(+) samples compared to HPV(-), whereas
“extracellular matrix” and “epithelium development” were up-regulated in HPV(-) samples. These
findings are consistent with what has been previously reported (Pyeon et al., 2007). Enrichment
analysis with cytobands identified several locations on 11q (11q13, 11q22.3 and 11q23.3) as en-
riched for genes up-regulated in HPV(-) samples. This may be driven by frequent focal amplifica-
tion of 11q13 and 11q22 and deletion of the far end of chr11q in HPV(-) samples (Fig 3.6) (The
Cancer Genome Atlas Network, 2015).
3.3.2 Unsupervised clustering revealed two HPV(+) subgroups
Unsupervised clustering using the most variably expressed genes among all samples revealed
three distinct groups (Fig 3.1A and Fig 3.7A). First, HPV(-) samples were distinguished from
HPV(+) samples, except for one HPV(-) sample which clustered with HPV(+) samples. The 18
HPV(+) samples separated into two clusters of 8 and 10 HPV(+) samples. These clustering results
were robust to various clustering metrics (Eucledian distance, centered or uncentered Pearson’s
correlation), linkages (single, average or robust) and different numbers of top variable genes used.
To assure that the clusters we found are generalizable, not limited to our cohort, we included
66 additional HPV(+) samples from The Cancer Genome Atlas (TCGA) HNC cohort, and then
performed unsupervised clustering on the 84 HPV(+) samples combined. Again, two clusters were
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robustly identified [Fig 3.1B and Figure 3.7B]. The clusters were not correlated with smoking
history, anatomical site, or tumor stage, but were correlated with gender and HPV type (α-level =
0.05) (Fig 3.1A and Table 3.1).
3.3.3 Differentially regulated genes and pathways between HPV(+) subgroups
We next characterized the molecular differences between the HPV(+) subgroups. Differential
expression analysis between the two HPV(+) clusters found 3515 genes significantly differentially
expressed (absolute fold change>2 and FDR<0.05). Up-regulated genes in one cluster were en-
riched for “immune response”, “mesenchymal cell differentiation” and various differentiation and
development-related terms; up-regulated genes in the other cluster were most significantly enriched
for “keratinocyte differentiation” and “oxidative reduction process”. Therefore, we name the clus-
ters HPV-IMU and HPV-KRT respectively. The top differentially expressed genes from each rele-
vant gene set are shown in Fig 3.1C, including BCL2 for mesenchymal differentiation, CDH3 and
TP63 for keratinization, and CDH1 and KRT16 for cell adhesion. To understand how the pathways
were dysregulated in the context of all HNC tumors, we compared each HPV(+) cluster to the other
cluster and HPV(-) samples, and identified pathways that were uniquely up- or down-regulated
(see methods). Enrichment testing results showed remarkably elevated immune response in HPV-
IMU consisting of increased T-cell activation, B-cell activation, lymphocyte activation, uniquely
repressed mesenchymal differentiation and extracellular matrix-related expression in HPV-KRT;
it also showed increased keratinization/epidermal differentiation and oxidative-reduction process
gene expression in HPV-KRT relative to HPV-IMU, with mixed expression in the HPV(-) samples
(Fig 3.1D). Multidimensional scaling analysis revealed that the HPV-KRT subgroup was overall
more similar to the HPV(-) samples (Fig 3.1B). Although we were underpowered to compare most
epidemiologic characteristics, we observed that HPV-KRT patients were more likely female and
more likely to be type HPV16 compared to HPV-IMU patients.
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3.3.4 HPV(+) subgroups correlate with HPV integration, E2/E4/E5 expression levels, full-length
E6 percent and E6 activity.
We described HPV genic integration status and integration sites with VirusSeq (Chen et al.,
2013b) using RNA-seq data for the HPV(+) tumors. Nine of the 18 UM and 41 of the 66 TCGA
HPV+ samples were found to contain at least one genic HPV integration site, hereafter denoted
as genic-integration. Surprisingly, cluster HPV-KRT had more samples with genic-integration (7
out of 10; 70%) than cluster HPV-IMU (2 out of 8; 25%). The same difference was observed
for TCGA data, where cluster HPV-KRT had 32 out of 41 (78%) with a genic-integration and
HPV-IMU had 9 out of 25 (36%) (Fig 3.2A). This difference in genic-integration was significant
between subgroups (combined p-value=0.0001; Fisher’s exact test).
We next tested whether any of the early HPV genes (E1, E2, E4, E5, E6, E7) were differentially
expressed between the subgroups. Of these we found that E2, E4, and E5 had significantly lower
expression in the HPV-KRT subgroup (E5 in Fig 3.2B, and E2 and E4 in Fig 3.8B,C). HPV inte-
gration frequently associates with loss of E2, E4, and/or E5 (zur Hausen, 2002). Since the HPV-
KRT cluster had more genic integration events than HPV-IMU, this result is consistent with the
difference in genic integration events. Upon closer examination, 4 of the 9 UM genic-integration-
positive samples and 22 of the 41 TCGA samples displayed lost expression of E2/E4/E5 (Fig
3.8A).
It is known that E6 may be expressed in either of two main forms: a full-length E6 isoform and
various spliced isoforms, together referred to as E6*, which have different functions not yet fully
understood. We next asked whether the ratio of full-length E6 to total E6 expression correlates
with subgroup membership (Fig 3.8D; see supplementary methods for details). Because the full-
length E6 percentages differed significantly by HPV types (Fig 3.8E), we restricted our analysis to
only the most prevalent HPV type, HPV16 (82% of all cases). HPV-KRT has significantly lower
full-length E6 percent than HPV-IMU (Fig 3.2C) (Wilcox rank sum test p =0.001), suggesting
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that HPV-KRT expresses less full-length E6 transcript and more spliced form E6*. Although the
full-length E6 percent was different between subgroups, total E6 expression levels measured by
RNA-seq was not (Fig 3.2D). Since the expression levels were quantified using RNA levels, it may
not reflect the actual E6 protein activity level in the cell. We took advantage of a published study
by Duffy et al (Duffy et al., 2003) of 51 genes (35 down and 16 up) regulated by E6, to calculate
an E6 activity score for each tumor sample (see supplementary methods). Overall, the E6 score
was significantly higher in HPV-IMU, indicating elevated E6 activity in HPV-IMU (Fig 3.2E,F;
p=2.6e-7). Interestingly, the genes down-regulated by E6 in Duffy’s study were especially more
repressed in HPV-IMU than HPV-KRT (Fig 3.2E).
3.3.5 Correlation of subgroups with copy number alterations and PIK3CA mutation
Examining genomic properties of the two HPV(+) subgroups allowed us to further compare
them with the HPV(-) HNC samples. Somatic copy numbers were obtained for all samples by
analyzing SNP-array data from tumors and blood (see Methods). In our sample of 36 tumors,
HPV(-) samples tended to harbor more copy number gains than HPV(+) samples (Fig 3.3A). In
addition to the commonly observed copy number changes associated with HPV status (gain of 3q,
5p, 8q in HPV(-) tumors and loss of 11q and 13q in HPV(+) tumors) (The Cancer Genome Atlas
Network, 2015), we found substantial differences between the two HPV(+) subgroups. Overall,
HPV-KRT tumors tended to have more amplifications than HPV-IMU. Particularly at the chromo-
somal arm level, HPV-KRT had more amplifications on all or a significant portion of chr3q than
subgroup HPV-IMU (p=1.7e-5, Wilcoxon test). In addition, HPV-IMU had frequent copy number
loss on chr16q, which was completely absent in HPV-KRT and HPV(-) samples. Differences in
chr3q CNA gain and chr16q CNA loss were also observed in the respective HPV(+) TCGA sub-
groups (Fig 3.3B). To determine if the CNAs affected gene expression differences, we asked what
percent of the genes on chr3q and chr16q were up versus down-regulated. Out of the 693 and
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427 genes on chr3q and chr16q, 148 (21%) and 132 (31%) genes were significantly up-regulated
in HPV-KRT compared to HPV-IMU, respectively; in contrast, a much smaller percent of genes
were down-regulated (7% and 5%) (Fig 3.3C,D). This is quite distinct from the opposite arms of
these chromosomes, 3p and 16p, where nearly equal percentages of genes were up and down reg-
ulated. The same trends were observed for TCGA data (Fig 3.3C,D). This suggests that the gain
and loss of copy numbers in part drove the expression differences between the two subgroups. Us-
ing neoplasm-related gene annotations from Gene2Mesh (Ade, AS; Wright, ZC; States, 2007), we
found 33 oncology-related genes, including TNSF10, PIK3CA, TP63 and MUC4 on chr3q, and
MMP2, CDH1, NQO1 and CDH13 on chr16q (Table 3.2). Nineteen of the 33 genes were also
differentially expressed between the clusters.
To investigate if there were any differences in gene mutation frequencies between the two
subgroups, we analyzed expressed, non-synonymous mutations from the RNA-seq data. We also
obtained TCGA gene-level somatic mutation data from Xena UCSC (Goldman et al., 2015). None
of the genes had a mutation difference greater than 20% in both cohorts, except for oncogene
PIK3CA (Fig 3.4A). PIK3CA had a mutation in a striking 60% of samples from the HPV-KRT
subgroup and 0% in HPV-IMU for the UM cohort. In TCGA, the difference was smaller (37%
in HPV-KRT versus 16% in HPV-IMU), however still appreciable (Fig 3.4B). Five of the 6 UM
PIK3CA mutations were known activating mutations (E545K, E545G and E542K), while the re-
maining mutation has unknown effect (E81K). Similarly, 17 out of the 19 mutations from TCGA
were known activating mutations. Additionally, PIK3CA is located on chr3q, which was also
found to have more amplifications in HPV-KRT. Not surprisingly, the copy numbers of PIK3CA
were higher in HPV-KRT (Fig 3.4C). Together, these two results strongly suggest up-regulated
PI3-kinase activity in the HPV-KRT tumors.
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3.3.6 Characteristics associated with HPV(+) subgroups and patient survival
Summarizing and visualizing all of the above findings, we observe that although the clusters
can be robustly separated by expression patterns, there remains substantial heterogeneity within
each subgroup for each variable (Fig 3.5A). For example, we created an epithelial-to-mesenchymal
transition (EMT) score for each tumor that combines the expression levels of the epithelial and
mesenchymal differentiation genes (see Methods). While the HPV-KRT subgroup clearly had
lower EMT scores overall, there was substantial variation in scores, especially among the TCGA
cohort. HPV-IMU has higher levels of immune response (represented in Fig 3.5A by an overall T
cell score), frequent chr16q loss, less viral integration in an expressed genic region, more E2/E5,
and higher BCL2 gene expression. Except for immune response and a stronger EMT signature, all
other attributes for HPV-IMU were correlated with better prognosis in the literature (Fig 3.5B and
Discussion). Because the elevated immune response in HPV-IMU could be an indication of higher
infiltration of cytotoxic T-cells, we calculated a T-cell activation score for each tumor based on
196 genes from the GO term “T-cell activation” (see Methods). Using overall survival data from
TCGA, we found that TCGA HPV(+) tumors with high T-cell activation scores had better overall
survival than those with low T-cell activation scores (Fig 3.5C; p<0.05). Although we did not find
a significant difference in overall survival between HPV-KRT and HPV-IMU with the same TCGA
data, HPV-KRT tended to have worse overall survival than HPV-IMU (Fig 3.5D), consistent with
the general predictions from literature. Lack of a significant difference could be due to the poor
follow-up data available from TCGA, or due to truly similar overall survival between subgroups.
In either case, the many above-described differences strongly suggest that different therapies may
best benefit patients within each subgroup.
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3.4 Discussion
Head and neck squamous cell carcinomas represent a heterogeneous disease that consists of two
molecular and clinically distinct entities distinguished by HPV infection. Due to a lack of HPV
information and/or a small number of HPV(+) cases in most previous studies, attempts to identify
tumor subtypes in HNCs have often neglected HPV as an important variable. Two published
studies that have identified within-HPV(+) subtypes with high-dimensional genomics data (Keck
et al., 2015; Pyeon et al., 2007) were unable to comprehensively describe molecular differences
between the HPV(+) subtypes. Particularly, it remained unclear how these subtypes correlated
with HPV characteristics, and the likely cause for their distinct behaviors. With unsupervised
clustering analysis, we independently identified two robust HPV(+) subgroups with our cohort that
persisted when we applied the same algorithm to the TCGA cohort. Although our clusters are
constructed on RNA-seq data which has a better signal-to-noise ratio than microarrays, they share
great similarity with the two HPV(+) clusters found in Keck et al. (Keck et al., 2015). We observed
similar differences between the two clusters in immune response, mesenchymal differentiation
and keratinization, and copy number changes in PIK3CA and TP63. In addition to providing an
independent source validating the existence of two HPV(+) subtypes, we greatly expanded the
depth of characterization by comprehensively profiling the expressed mutations, whole-genome
CNAs and exploring HPV characteristics. Most importantly, our findings highlight two oncogenic
paths in HPV(+) tumors that are likely driven by differences in HPV characteristics, chromosome-
arm level CNAs, and PI3K pathway activity.
The most significant difference in expression between the HPV(+) clusters is the up-regulation
of mesenchymal and immune-response genes in the HPV-IMU group, and keratinization and
oxidation-reduction process in HPV-KRT. In fact, all of these pathways are explained by the biol-
ogy of HPV carcinogenesis. The HPV E6 oncoprotein is reported to down-regulate a large num-
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ber of genes involved in keratinocyte differentiation, and up-regulate genes normally expressed
in mesenchymal lineages (Duffy et al., 2003). In addition, HPV type16 spliced variant E6* in-
duces oxidative stress (Williams et al., 2014). Our analysis revealed that the HPV-IMU group had
higher E6 activity whereas HPV-KRT had higher levels of the spliced forms of E6, E6*, which
is concordant with the repressed keratinization and induced mesenchymal differential pathways in
HPV-IMU and higher oxidation-reduction response in HPV-KRT. The HPV-KRT group was also
more likely to have a detected HPV integration event, which may drive the expression of more
E6* and less full-length E6. Our results regarding E6 activity scores also imply that the RNA-seq
quantification of E6 expression levels may not adequately reflect E6 activity in the cells.
The higher immune response in HPV-IMU may be particularly relevant, as it was shown
that HPV(+) HNCs have a different immune profile than their HPV(-) counterparts, featuring
higher numbers of infiltrating CD8+ T lymphocytes, myeloid dendritic cell and proinflammatory
chemokines (Partlova´ et al., 2015). Together, these are hypothesized to promote better response to
treatment in HPV(+) patients (Partlova´ et al., 2015). In our study, we showed that stronger immune
response could indeed predict better overall survival (Fig 3.5C). We hypothesize that when HPV
shifts from the initial episomal form to an integrated transcribed form, the inflammatory/immune
response towards HPV concurrently weakens. That may explain why HPV-IMU, having fewer
HPV-integration events, have a stronger immune response. The stronger inflammatory/immune
response in HPV-IMU group may partially explain why HPV(+) HNCs overall have better prog-
nosis.
Another key finding of our study is that more chr3q amplifications were observed in HPV-
KRT, whereas frequent chr16q deletions were found in HPV-IMU. These two signature copy num-
ber changes were evident in the independent UM and TCGA cohorts, validating these findings.
However, the functional significance behind the associations of the copy number signatures with
subgroups is unclear. One possible explanation could be that the change in copy number of a
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few key genes on chr3q and chr16q favors the survival/growth of tumor cells in each respective
subgroup, thus they were each positively selected in the tumor evolution of each subtype. We
queried a tumor associated gene (TAG) database (Chen et al., 2013a) for the percent of oncogenes
and tumor suppressor genes (TSG) on chr3q and chr16q, and interestingly, the majority of TAGs
on chr3q are oncogenes (14 oncogenes, 4 TSGs, and 9 unknown) whereas most TAGs on chr16q
are TSGs (12 TSGs, 1 oncogene, and 2 unknown). This preliminary result suggests that the am-
plification of chr3q and deletion of chr16q are both more likely to promote tumor growth either
by increasing the copies of oncogenes or decreasing that of TSGs. Examining the genes more
closely, we found that on chr3q, several key cancer genes stood out as having anti-apoptotic func-
tion, such as PIK3CA, TP63, MUC4, which may promote cancer cell survival for HPV-KRT as a
result of chr3q amplification. Particularly Np63 (an isoform of p63) is dominantly over expressed
in HNC and plays a pivotal anti-differentiation and anti-apoptosis role in the formation of HNC
(Rothenberg and Ellisen, 2012). On chr16q, CDH1, CDH13, and BCAR1 were associated with
cell adhesion, thus the attenuation of their expression by copy number loss in HPV-IMU likely
strengthens EMT properties in this subtype.
When we investigated the mutation difference between the clusters, PIK3CA was found to be
the top hit. PI3-kinase signaling pathway has previously been implicated in tumorigenesis and
PIK3CA activating mutations have been found in various cancer types (Yuan and Cantley, 2008).
We discovered that HPV-KRT subtype not only has more PIK3CA activating mutations, but also
higher copy numbers of PIK3CA, suggesting elevated PIK3CA activity is important especially
in the HPV-KRT group, and which may imply a difference in tumorigenesis between the two
subgroups.
One limitation of our study is the lack of patient survival data. UM HPV(+) tumors were
collected between 2011 - 2013, and due to high overall survival in this group, we are not yet
able to perform meaningful risk analysis on these patients. The TCGA cohort has 66 HPV(+)
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samples, however most of the patients were lost to follow-up after 12 months, therefore effectively
reducing the sample size and conferring the analysis a much lower power. Nevertheless, HPV-KRT
patients are thought to have worse outcome based on several lines of evidence. First, HPV-KRT’s
expression profiles (Fig3.1B) and copy number profiles, particularly gain on chr3q (Fig 3.3A), are
more similar to those of HPV(-) patients, who are known to have worse treatment response and
survival. HPV-IMU has more frequent chr16q loss, which was reported to correlate with better
survival for patients with oropharyngeal SCCs (Klussmann et al., 2009). In addition, HPV-KRT
has more detected virus integration events, which may be partially caused by a higher level of
genomic instability (or vice versa). In cervical cancer, it was found that patients who only had
integrated HPV expression had a trend towards worse disease free survival compared to patients
with both integrated and episomal HPV forms (Shin et al., 2014). Studies on HNCs showed worse
recurrence-free survival for HPV(+) tumors with low levels of E2 (Ramqvist et al., 2015) and
E5 (Um et al., 2014), markers for integrated HPV. HPV-IMU has much higher levels of BCL2
expression than HPV-KRT, which has been reported to correlate with more favorable outcome in
HNCs (Camisasca et al., 2009; Wilson et al., 2001). Altogether, this network of correlated events
and pathways imply that the HPV-IMU and HPV-KRT subtypes proceed through carcinogenesis
using different driving forces, and are thus likely to benefit from different treatment strategies.
While patients falling in the HPV-KRT subgroup may benefit more from future immunotherapies,
HPV-IMU may benefit from treatment deterring metastasis associated with EMT. Furthermore,
our results strongly suggest that most of these differences are driven by the mode of HPV infection
itself.
In conclusion, we identified two subtypes of HNC HPV(+) tumors based initially on expression
patterns from RNA-seq data, but found to strongly correlate with a substantial number of important
molecular markers, including viral characteristics, CNAs, and oncogenic PIK3CA mutations. This
study takes a significant step towards decoding the molecular heterogeneity among HPV-associated
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HNCs. Our work has important translational implications that could guide biomarker development
and precision medicine for HPV(+) HNC patients.
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Figure 3.1: Identification of two HPV(+) subgroups and pathway differences between them.
(A) Hierarchical clustering (shown here) and consensus clustering (Fig S1A) revealed two distinct
HPV(+) clusters in the UM cohort. The clusters were not correlated with anatomical site or smok-
ing. (B) Multi-Dimensional Scaling plot displaying the relationship among combined UM (n=36)
and TCGA (n=66) samples by subgroup. The HPV-KRT subgroup is more similar to the non-HPV
samples than is the HPV-IMU subgroup. (C) Heatmap showing representative genes/pathways dif-
ferent between HPV-KRT and HPV-IMU. (D) Heatmap showing the top differentially expressed
genes (and pathways) among the three clusters. The genes were grouped by their expression sig-
natures across the three clusters.
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Figure 3.2: HPV(+) subgroups correlate with several HPV characteristics. (A) Barplot show-
ing HPV-KRT tumors were more likely to have a detected genic-integration than HPV-IMU. (B)
boxplot of HPV E5 expression levels; HPV-KRT had lower E5 expression than HPV-IMU. (See
Fig S2B for plots of E2 and E4.) (C) boxplot of HPV E6 full-length percent for HPV type 16
samples. HPV-KRT had significantly lower E6 full-length percent than HPV-IMU. (D) barplot of
HPV E6 expression levels. (E) Heatmap of the E6-regulated genes from Duffy et al., showing
genes repressed by E6 were lower expressed in HPV-IMU. (F) boxplot of E6 activity score shows
overall higher E6 activity in HPV-IMU.
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Figure 3.3: HPV(+) subgroups differ by copy number alterations. (A,B) Heatmaps of somatic
copy numbers for UM (A) and TCGA (B) samples. The dark dashed lines highlight the regions that
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Figure 3.4: The HPV-KRT subgroup had more PIK3CA mutations and amplifications. (A)
Scatterplot showing the difference in mutation rates between subgroups for each gene. PIK3CA
was the only gene that had>20% difference in both cohorts. The difference was calculated by sub-
tracting the mutation rate in HPV-KRT from that of HPV-IMU. (B) Barplot showing the PIK3CA
mutation rates for each subgroup and cohort. (C) Boxplot showing that in both cohorts, HPV-KRT
had more PIK3CA copy number amplifications than HPV-IMU.
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Figure 3.5: Summary of characteristics that differ by HPV(+) subgroup, and prognosis. (A)
Heatmap of variables that correlated with HPV(+) subgroup. The columns represent samples which
are sorted by cluster, cohort, viral integration and PIK3CA mutation. E5 expression is the log10
transformed CPM values. (B) A table of observed features and associated publications suggesting
better prognosis for HPV-IMU for all but EMT. (C) Overall survival for TCGA tumors with high
and low T-cell activation scores. (D) Overall survival for HPV-KRT and HPV-IMU tumors from
TCGA cohort. (C,D) P-values were calculated using a univariate Kaplan-Meier log rank test.
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Figure 3.6: Focal amplification of chr11q13 and chr11q22 in HPV(-) tumors and far-end
deletion of chr11q in HPV(+) tumors. The top panel shows the gene expression fold changes
(log transformed) between HPV(-) and HPV(+) samples. Up-regulated genes in HPV(-) tumors is
colored in red and up-regulated in HPV(+) tumors is in blue. The bottom panel shows the CNA of
the tumors (divided in the middle by HPV status).
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Figure 3.7: ConsensusCluster Plus output for (A) UM and (B) UM+TCGA HPV(+) samples.
(A, B) The left-most figures show the tree structure for the selected k (k=3 for UM and k=2 for
UM+TCGA). The second-to-the-left figures show the tree structure for k=(optimal K)+1. In both
cases, the additional cluster only picks out trivial number of samples (one and five, respectively),
providing strong evidence that the selected k is most appropriate. The 3rd figures (second to the
right) show the consensus CDF for different k values, and the 4th (right-most) figures show the
relative change in the area under CDF when k increases.
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Figure 3.8: Correlation of clusters with HPV characteristics. (A) Plot of the expression levels
of E2/E4/E5, using color to represent viral genic integration status. Each gene is sorted across
samples by its expression value from low to high. (B,C) boxplots of HPV E2/E4 expression levels
by subgroup. (D) Illustration of how full-length E6 percentage is calculated. R1 and R2 are the
numbers of reads aligned to each interval. L1 and L2 are the lengths of the interval. R2/L2 is an
approximation of full-length E6 transcript abundance, whereas R1/L1 is an approximation of the
abundance of all E6 isoform. Full-length E6 percentage is calculated as in the formula shown. (E)
Boxplot showing the full-length E6 percentage by HPV type.
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Tables
Table 3.1: Patient demographics. *tests were performed between HPV-KRT and HPV-IMU for
both cohorts combined. Wilcoxon rank sum test was performed for age, whereas Fisher’s exact
test was used for other variables. For HPV type, HPV16 versus others combined was tested. For
anatomical sites, only oropharynx versus oral cavity was tested due to insufficient tumors from
other sites.
UM tumors TCGA tumors p-
value*
Total Non-HPV HPV-KRT HPV-IMU Total HPV-KRT HPV-IMU
36 18 10 8 66 41 25
Age
Median(std) 56.5(10) 55.5(6.8) 62.5(6.7) 58(10) 57(7.8) 0.38
Gender
Male 26 9 9 8 60 35 25 0.039
Female 10 9 1 0 6 6 0
HPV type
HPV16 14 9 5 55 37 18 0.022
HPV18 1 1 0 0 0 0
HPV33 1 0 1 8 3 5
HPV35 2 0 2 3 1 2
Anatomical
Site
Oropharynx 20 3(17%) 9(90%) 8(100%) 47 26(63%) 21 (84%) 0.051
Oral cavity 14 13(72%) 1(10%) 0 16 13(32%) 3(12%)
Larynx 2 2(11%) 0 0 1 0 1(4%)
Hypopharynx 0 0 0 0 2 2(5%) 0
Tumor
stage
I-II 5 4 0 1 10 6 4 0.33
III 3 1 1 1 7 3 4
IV 28 13 9 6 23 13 10
Unknown 23 13 10
Smoking
Never 7 3(17%) 3(30%) 1(13%) 22 11(27%) 11(44%) 0.66
Former 23 12(66%) 4(40%) 7(87%) 30 23(56%) 7(28%)
Current 6 3(17%) 3(30%) 0 13 7(17%) 6(24%)
Unknown 1 1
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Table 3.2: Neoplasm-associated genes on chr3q and chr16q (identified by gene2Mesh). The
‘logFC’, ‘p-value’ and ‘q-value’ columns are from testing the expression difference between HPV-
KRT and HPV-IMU tumors (UM and TCGA combined).
Symbol chr start end neoplasm
count
logFC p-value q-value
PIK3CA chr3 178866310 178952497 6 0.611423753 9.47E-05 0.000438548
TP63 chr3 189349215 189615068 4 1.008705532 9.37E-07 7.01E-06
TNFSF10 chr3 172235144 172241265 3 0.902624175 3.43E-05 0.000177248
UMPS chr3 124449212 124468119 3 0.810107441 6.98E-11 1.18E-09
MUC4 chr3 195473637 195538844 2 3.134042961 3.55E-10 5.33E-09
MFI2 chr3 196728611 196756687 2 -0.197088928 0.379116911 0.492929089
MME chr3 154797435 154901518 2 0.588142839 0.0913372 0.157720074
SOX2 chr3 181429711 181432223 1 -0.036159934 0.884715468 0.920307803
CLDN1 chr3 190023489 190040235 1 -0.318512837 0.205996477 0.304042693
TRPC1 chr3 142443265 142526729 1 -0.497394572 0.050235418 0.096794332
GCSAM chr3 111839687 111852152 1 NA NA NA
CLDN18 chr3 137729005 137752494 1 NA NA NA
CCNL1 chr3 156865585 156878482 1 0.477053726 0.000723821 0.002610024
ABCC5 chr3 183637723 183735727 1 1.077229262 3.59E-06 2.34E-05
THPO chr3 184089772 184095932 1 NA NA NA
ACPP chr3 132036210 132077690 1 1.432135514 3.05E-07 2.55E-06
UPK1B chr3 118892424 118924000 1 -1.514829696 0.000973055 0.003368935
TFG chr3 100428174 100467811 1 0.312782591 0.006510867 0.017190072
TM4SF1 chr3 149086804 149095568 1 1.218675059 8.72E-09 1.00E-07
CDH1 chr16 68771194 68869444 13 1.038000997 8.17E-12 1.61E-10
MMP2 chr16 55515473 55540586 7 -0.163938831 0.53907379 0.643135375
NQO1 chr16 69743303 69760533 4 2.290590728 1.80E-12 4.01E-11
WWOX chr16 78133326 79246564 2 -0.563230306 2.52E-05 0.000134277
CDH13 chr16 82660398 83830215 2 -0.605368955 0.038283574 0.077286453
CDH11 chr16 64980682 65155919 1 -0.663114206 0.027828681 0.059312651
ZFHX3 chr16 72816785 73082274 1 0.078619508 0.666940877 0.75105827
BCAR1 chr16 75262927 75285526 1 1.217312903 1.38E-19 9.40E-18
TUBB3 chr16 89988416 90002505 1 1.270361004 9.00E-06 5.36E-05
CYLD chr16 50775960 50835846 1 0.302150962 0.027459531 0.058596546
HPR chr16 72097124 72111145 1 NA NA NA
TOX3 chr16 52471917 52581714 1 -2.167580909 0.001362538 0.004512094
CBFB chr16 67063049 67134958 1 0.571606939 5.00E-08 4.94E-07
MC1R chr16 89984286 89987385 1 1.162756786 6.32E-09 7.51E-08
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CHAPTER IV
Genomic binding and regulation of gene expression by the
thyroid carcinoma-associated PAX8-PPARG fusion protein
4.1 Introduction
Thyroid carcinoma is the most common endocrine malignancy, and its incidence has increased
nearly 3-fold since 1990 (Enewold et al., 2009; Howlader et al., 2015). The majority of thyroid
carcinomas contain one of a small number of driver mutations, such as BRAF or RAS mutations,
gene fusions involving RET, or gene fusions between PAX8 and PPARG (reviewed in (Vu-Phan
and Koenig, 2014)). The PAX8-peroxisome proliferator-activated receptor gamma (PPARG) gene
fusion is a consequence of a translocation between chromosomes 2 and 3, and is found in ∼
30% of follicular thyroid carcinomas and ∼ 5% of follicular variant papillary carcinomas. The
resulting PAX8-PPARG fusion protein (PPFP) is unusual in that it is the fusion of two transcription
factors and it retains the DNA binding domains (DBDs) of both parent proteins (Kroll et al., 2000).
Thus, at least in principle, PPFP should be capable of binding to PAX8 and PPARG response
elements and potentially regulating target genes of both transcription factors. However, no data
exist to define the genomic binding sites of PPFP, and the largest study characterizing global gene
expression patterns in human PPFP carcinomas consisted of only 7 cases (Giordano et al., 2006).
The work in Chapter IV is published as Zhang Y*, Yu J*, Lee C*, Xu B, Sartor MA, Koenig RJ. “Genomic bind-
ing and regulation of gene expression by the thyroid carcinoma-associated PAX8-PPARG fusion protein.” Oncotarget.
2015 Dec 1;6(38):40418-32. doi: 10.18632/oncotarget.6340.(*equal contribution)
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Given these limited data, the mechanism of oncogenesis is poorly understood (reviewed in (Raman
and Koenig, 2014)).
PAX8 is a member of the paired box family of transcription factors and is essential for thyroid
gland development (Macchia et al., 1998; Pasca di Magliano et al., 2000). In the mature thyroid,
PAX8 drives the expression of numerous thyroid-specific genes (Pasca di Magliano et al., 2000).
PPARG is a member of the nuclear receptor family of transcription factors. It has no identified role
in the normal thyroid and is expressed at extremely low levels in that organ. PPARG is the master
regulator of adipogenesis (Rosen et al., 1999), and also plays an important role in macrophage
development, where it promotes an anti-inflammatory phenotype (Corzo and Griffin, 2013). Syn-
thetic agonist ligands for PPARG such as pioglitazone are insulin sensitizers and hence are used to
treat type 2 diabetes. PPARG ligands also are ligands for PPFP. In a mouse model of PPFP thy-
roid carcinoma, pioglitazone was highly therapeutic, greatly shrinking thyroid size and prevent-
ing metastatic disease (Dobson et al., 2011). Pioglitazone was strongly pro-adipogenic in these
murine thyroid tumors, converting the thyroid cells into lipid-laden adipocyte-like cells. Although
this indicates that PPFP is strongly PPARG-like in the presence of pioglitazone, the mechanism
underlying the therapeutic efficacy of pioglitazone in this mouse model of PPFP thyroid carcinoma
is not known.
There are no existing cell lines from PPFP thyroid carcinomas. However, PPFP has been stably
expressed in the PCCL3 rat thyroid cell line at a level comparable to that in human thyroid cancers,
herein denoted PPFP cells (Vu-Phan et al., 2013). PPFP expression confers upon PCCL3 cells an
increased ability to invade through Matrigel and to form colonies in soft agar, both signs of cellular
transformation (Vu-Phan et al., 2013). Thus, PPFP cells are a useful cell culture model to study
PPFP-dependent oncogenesis, and potentially, the response to pioglitazone. PCCL3 cells also have
been used to create cell culture models of thyroid carcinomas caused by oncogenic driver mutations
in BRAF (Mitsutake et al., 2005) and RAS (Vitagliano et al., 2006), and RET gene fusions (Croyle
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et al., 2008).
Here, we have used RNA deep sequencing (RNA-seq) to study the gene expression of PPFP
cells versus control empty vector (EV) cells, cultured with and without pioglitazone. We also per-
formed chromatin immunoprecipitation-deep sequencing (ChIP-seq) to identify the PPFP binding
sites within the PCCL3 cell genome, and integrated the results with the gene expression data and
publicly-available PAX8 and PPARG ChIP-seq data. The results provide novel insights into the
transcriptional regulatory activity of PPFP, its oncogenic actions, and the response to pioglitazone.
4.2 Materials and methods
4.2.1 Cell culture
PCCL3-PPFP cells stably express human PPFP with a 3xMyc tag at the amino terminus, and
PCCL3-EV cells have been stably transfected with the empty vector (Vu-Phan et al., 2013). PPFP
and EV cells were cultured as previously described (Vu-Phan et al., 2013). In some experiments,
the cells were treated with 1 M pioglitazone (from a 1 mM stock solution in DMSO) or vehicle for
the times indicated prior to harvest.
4.2.2 Antibodies
Antibodies were obtained from the following sources as indicated: Cell Signaling Technology
(Danvers, MA) beta actin #8457, Ccnb1 #12231, Hes1 #11988, Myc tag #2276, Notch1 #3608 and
Plk3 #4896; Proteintech (Chicago, IL) Acaa2 #11111-1-AP and Icam5 #12759-1-AP; Sigma (St.
Louis, MO) Foxe1 #SAB2100840; and Life Technologies (Grand Island, NY) Cdk1 #MA5-11472
and Plin1 #PA1-1051.
4.2.3 Flow cytometry
DNA content was analyzed by propidium iodide staining and oxidative stress was analyzed
with CellROX Deep Red per the vendor’s protocols (Life Technologies). For the oxidative stress
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experiments, the cells were cultured ± 1 µM pioglitazone for 2 days and ± 50 µM TBHP for the
final hour. Approximately 10,000 cells per condition were analyzed in the University of Michigan
Comprehensive Cancer Center Flow Cytometry Core on a MACSQuant cytometer.
4.2.4 ChIP-seq assay
PPFP cells were cultured with pioglitazone for 16 hours, crosslinked with formaldehyde, soni-
cated to an average DNA size of 300 to 500 bp, and immunoprecipitated with anti-Myc antibody at
1:500 overnight at 4C using the protocol of Upstate Biotechnology (Lake Placid, NY), except that
immunoprecipitation was performed with Dynabeads G (Life Technologies). ChIP and input DNA
were used for next generation library construction and DNA sequencing on an Illumina HiSeq
2000 per the manufacturer’s protocol using 50 nt single-end reads, performed by the University of
Michigan DNA Sequencing Core. Four samples were barcoded and run on one lane, obtaining an
average of 31 million reads per sample.
4.2.5 RNA-seq assay
PPFP and EV cells were treated with 1 µM pioglitazone or vehicle for 16 hours. Total RNA was
prepared using an RNeasy Mini Kit (Qiagen). Three independent experiments were performed.
Library construction (Illumina TruSeq RNA) and sequencing on an Illumina HiSeq2000 using 50
nt paired end reads were per the manufacturer’s protocols, performed by the University of Michigan
DNA Sequencing Core. The samples were barcoded and loaded onto the same run, with all samples
from each experiment run on the same two lanes; an average of 88 million reads were obtained per
sample. PPFP ChIP-seq and RNA-seq data were deposited in Gene Expression Omnibus (GEO)
with the accession ID GSE70354.
110
4.2.6 ChIP-seq data analysis
The quality of reads were assessed using FastQC (Andrews, 2015). There were 29.3 and 33.5
million reads sequenced for PPFP ChIP and input samples, respectively. ChIP-seq and input reads
were aligned to the rat reference genome (rn4) using BWA (version 0.5.9-r16) with default options.
MACS2 (2.0.10.20131216beta) was used to call peaks using a q-value <0.05 cutoff (Feng et al.,
2012). Peaks were then filtered by PePr (1.0.5) (Zhang et al., 2014) to remove artifacts due to
high PCR duplications. Peak boundaries were re-defined as 150 bp from the peak mode, and over-
represented motifs were identified from the peaks by MEME(4.9.1), searching for the top 10 motifs
with minimal width of 10bp and maximal width of 18bp. The most over-represented motif (shown
in Fig 4.5A) was very close to PPARG motif previously reported (Lefterova et al., 2008; 2010;
Nielsen et al., 2008) and was used as the position weight matrix (PWM) for the PPARG motif in
all following analyses. Motif occurrences in the peaks were detected by FIMO(4.9.1) using default
parameters and the PWM output from MEME. The presence of PPARG and PAX8 motifs in PPFP
peaks was detected with the MEME/FIMO suite, and was also independently discovered using
another motif discovery tool, HOMER (Heinz et al., 2010), as the top 2 known enriched motifs. Of
the top 35 motifs found by HOMER, none were related to Myc, assuring that potential nonspecific
binding caused by using a Myc tag antibody should be negligible.
Peaks were annotated to the genome with respect to gene features using an adapted HOMER
script. If a peak had two or more annotations, a priority was assigned based on the order from
left to right in Figure 4.4, as follows: -1 to + 1kb (relative to the TSS), -1 to -5kb, -5 to -10kb,
exon, UTR, intron, and intergenic. We define “intergenic” as outside of the region between 10kb
upstream from a TSS and its 3’UTR.
PAX8 ChIP-seq raw read data (GSE26871) were downloaded and analyzed as described above.
The PAX8 motif (shown in Fig 4.5A) was found as the top hit by MEME searching for the
top 10 overrepresented motifs with minimal width of 10bp and maximal width of 15bp. The
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PAX8 motif identified here closely matches that previously published (Ruiz-Llorente et al., 2012).
PPARG ChIP-seq peaks from mouse adipocyte and macrophage cells were downloaded from GEO
(GSE21314).
4.2.7 RNA-seq data analysis
Quality checks were performed on RNA-seq reads with RSeQC (2.3.9) (Wang et al., 2012).
The reads were aligned to rn4 with tophat2 (v2.0.11) and gene read counts were quantified by
HTseq (0.6.1p1) (Anders et al., 2015) with option “-m intersection-strict” and normalized using
the edgeR (3.2.4) Bioconductor package (McCarthy et al., 2012). Differential expression analysis
was performed using edgeR with tagwise dispersion for each pairwise comparison of PPFP cells
or EV cells treated with and without pioglitazone (four comparisons total). False discovery rate
(FDR) was controlled using the Benjamini-Hochberg method (Yoav Benjamini, 1995).
4.2.8 Gene set enrichment testing
P-values from differential expression analysis from edgeR using the RNA-seq data were input
into LRpath (Kim et al., 2012; Sartor et al., 2009) for gene set enrichment testing. LRpath is
a logistic-regression-based method that models the relationship between the log-odds of genes
belonging to a gene set and their -log(p-values). We used the directional test option in LRpath,
and tested GO terms and KEGG pathways with each pairwise comparison of PPFP cells or EV
cells treated with and without pioglitazone. Gene sets satisfying FDR ≤ 0.05 were considered to
be significant. Gene set enrichment testing of the ChIP-seq data was performed with ChIP-Enrich,
a logistic-regression-based method that uses a smoothing spline to empirically adjust for gene
locus length and mappability (Welch et al., 2014). Gene set enrichment results were corrected for
multiple testing using the Benjamini-Hochberg FDR correction. Only gene sets with ≤ 500 genes
were reported, as gene sets with larger numbers of genes are more general and provide limited
biological insight.
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4.3 Results
4.3.1 Overview of genes regulated by PPFP in the absence and presence of pioglitazone
An RNA-seq analysis was performed on RNA from PPFP cells versus EV cells treated with
or without pioglitazone. PPFP regulated the expression of 1541 genes (628 up, 913 down) in the
comparison of PPFP cells versus EV cells without pioglitazone (FDR <0.05 and fold change >2).
When both cell lines were cultured with pioglitazone, slightly more genes were differentially ex-
pressed (2078; 877 up, 1201 down). In a comparison of PPFP cells cultured with versus without
pioglitazone, 250 genes were differentially expressed (95 up, 155 down). The differentially ex-
pressed genes in all of these comparisons are highly overlapping (Figure 4.1). In contrast, there
were no differentially expressed genes in EV cells cultured with versus without pioglitazone, con-
sistent with the very low expression level of endogenous PPARG in thyroid cells and the specificity
of pioglitazone. Figure 4.1 shows that 156 of the 250 genes differentially expressed in PPFP cells
cultured with versus without pioglitazone also are differentially expressed in PPFP cells versus
EV cells cultured without pioglitazone. The PPFP and pioglitazone-induced changes are in the
same direction for 130 (83%) of these 156 genes (48 up, 82 down), indicating that pioglitazone
reinforces most of the PPFP-induced changes. However, for 26 genes (17%), the changes were in
opposite directions such that pioglitazone partially or completely reversed the effects of PPFP.
4.3.2 PPFP regulates processes related to oncogenesis
Gene expression changes in PPFP cells versus EV cells in the absence of pioglitazone poten-
tially are relevant to the oncogenic actions of PPFP. We subjected this comparison to a functional
enrichment analysis using Gene Ontology (GO) terms and KEGG pathways (Kim et al., 2012; Sar-
tor et al., 2009). We identified 162 enriched gene sets (FDR<0.05), 55 of which were induced by
PPFP and 107 repressed. The 15 induced and 15 repressed gene sets with the lowest q-values are
shown in Table 4.1. Many of the induced gene sets involve processes directly related to cancer biol-
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ogy. For example, gene sets related to the cell cycle include MCM complex, deoxyribonucleotide
biosynthetic process, DNA replication, and others. Three cell cycle-related genes within these
gene sets (Ccnb1, Cdk1 and Plk3) were investigated further and were also found to be induced at
the protein level by PPFP (Figure 4.2). Consistent with the enrichment of cell cycle-related gene
sets, cellular DNA content analysis by flow cytometry demonstrated that a greater fraction of PPFP
cells than EV cells are in the S and G2/M phases of the cell cycle, and a lesser fraction are in G1
(Figure 4.3).
Other highly significant cancer-related processes were related to proteasome/protein folding,
immune function and oxidative stress (Table 4.1). Gene sets related to mitochondria/lipids also
were enriched, consistent with PPARG-like activity of PPFP. We confirmed the induction by PPFP
of two such PPARG target genes, Acaa2 and Plin1, at the protein level (Figure 4.2). Twenty-two of
the 107 repressed gene sets contain the word morphogenesis, differentiation or development (Table
4.1), consistent with the expectation that, as an oncogene, PPFP enforces a less differentiated state.
The repressed genes include several involved in thyroid differentiation, including Fgfr2 (Celli et al.,
1998), Hhex (Martinez Barbera et al., 2000), Foxe1 (Clifton-Bligh et al., 1998), Hes1 (Carre et al.,
2011) and Notch1 (Porazzi et al., 2012), the latter three of which were confirmed at the protein level
(Figure 4.2). The repressed gene sets also include cell adhesion, extracellular matrix, and several
related terms. Repressing these gene sets could facilitate invasion and metastases. We confirmed
PPFP-dependent repression of the cell adhesion protein Icam5 at the protein level (Figure 4.2).
4.3.3 PPFP can induce or repress PAX8-regulated genes
PAX8 induces thyroid-specific genes such as Tg, but only limited data exist to define PAX8-
responsive genes more broadly. In a previous publication (Ruiz-Llorente et al., 2012), siRNA
knockdown of PAX8 in PCCL3 cells yielded 601 differentially expressed genes that also were
tested in our data set. In general the magnitude of change was modest in the siRNA experiment,
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with 296 genes showing a fold change >1.2 (siPAX8 induced 175 genes and repressed 121). We
determined what fraction of these siPAX8-responsive genes was differentially expressed in PPFP
cells versus EV cells cultured without pioglitazone (using FDR<0.05 and fold change >1.5 as cut-
offs). As shown in Table 4.2, slightly more than half of siPAX8-regulated genes are regulated by
PPFP, and the direction of regulation is discordant about 2/3 of the time (p=0.00015 for observing
this level of discordance by chance; Fisher’s exact test). Since induction by siPAX8 implies re-
pression by PAX8 and vice versa, the data indicate that PAX8 and PPFP regulate gene expression
in the same direction for ∼ 2/3 of the genes, and in opposite directions for ∼ 1/3.
PPFP regulates genes related to fatty acid metabolism and mitochondrial function, especially in
the presence of pioglitazone The 55 induced gene sets in the comparison of PPFP cells versus EV
cells in the absence of pioglitazone include several related to mitochondria, fatty acids and lipids,
such as mitochondrial envelope, lipid particle, and cellular response to fatty acid (Table 4.1). The
induced genes in these gene sets include adipocyte PPARG target genes such as Acaa2 and Plin1,
demonstrating that PPFP is PPARG-like on a subset of target genes. This is consistent with the
fact that several PPARG target genes have been shown to be induced in human PPFP thyroid
carcinomas (Giordano et al., 2006). However, the PPARG-like activity of PPFP is much more
striking in the presence of pioglitazone. We found that 117 gene sets are enriched in the comparison
of PPFP cells cultured with versus without pioglitazone (52 induced, 65 repressed). The 10 most
significant gene sets are all induced by pioglitazone, and all relate to fatty acid metabolism and
PPAR activity (Table 4.3). Among the PPARG target genes in these gene sets, we confirmed the
inductions of Acaa2 and Plin1 at the protein level, as noted previously (Figure 4.2).
4.3.4 Overview of the PPFP cistrome
We performed ChIP-seq analysis on PPFP to begin to understand the DNA binding properties
of PPFP and the genes it is likely to regulate through direct interactions. Using an FDR <0.05, we
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identified 20,277 PPFP peaks in the PCCL3 cell genome. As has been found previously for PAX8
(Ruiz-Llorente et al., 2012) and PPARG (Lefterova et al., 2008), most PPFP peaks are intergenic.
However, we observed an enrichment of PPFP peaks in genic regions, and most strikingly within 1
kb of transcription start sites (TSS’s) (2.9-fold enriched) (Figure 4.4). PPFP peaks also are enriched
2-fold from -5 to -1 kb of TSS’s and 1.7-fold in first introns, and are under-represented (0.8-fold) in
intergenic regions. Since PPFP contains DBDs from both PAX8 and PPARG, in principle it could
bind to the DNA motifs recognized by both transcription factors. This is what was observed, as
we identified the PPARG and PAX8 motifs de novo as the top two most overrepresented sequences
within the peak regions using HOMER (Heinz et al., 2010). Overall, 65% of PPFP peaks contain
a PPARG motif and/or a PAX8 motif, and these partially overlap (Figure 4.5A). An unexpected
finding was that 50% of the peaks with a PAX8 motif also contain a PPARG motif. This is in-
teresting because a much lower rate of PPARG motifs would be expected near PAX8 motifs if
PPFP uses only one of the two DBDs for every binding site. To investigate if the co-localizations
of the two motifs were due to false-positive matches of the motif position weight matrices to the
sequences, we examined the motif locations relative to the peak centers. The results show that
both the PAX8 and PPARG motifs are centered within these PPFP peaks, as would be expected if
both are functionally relevant to DNA binding (Figure 4.5B). This suggests that PPFP prefers to
bind to the subset of PAX8 motifs that have nearby PPARG motifs. To evaluate this further, we
took advantage of the fact that a ChIP-seq analysis has been published for PAX8 in PCCL3 cells
(Ruiz-Llorente et al., 2012). We first filtered the PAX8 peaks by whether they contained at least
one PAX8 motif, to remove potential false positive peaks that could confound the analysis. We
then asked what fraction of the PAX8 peaks that contain a PAX8 motif and do or do not overlap
with our PPFP peaks also contain a PPARG motif. As shown in Figure 4.5C, PPARG motifs are
enriched in the PAX8 peaks to which PPFP also binds (odds ratio=1.9, p-value<2.2e-16, Fisher’s
exact test), confirming that PPFP preferentially binds to the subset of PAX8 peaks that also contain
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a PPARG motif.
4.3.5 Overview of genes and gene sets containing PPFP peaks
PPFP peaks were found to encompass a number of known functional response elements in clas-
sic PAX8 and PPARG responsive genes. For example, PPFP peaks encompass the PAX8 response
element in the Tg promoter (Zannini et al., 1992) and the PPARG response element in the Aqp7
promoter (Kishida et al., 2001). One hundred sixty eight GO terms were identified as enriched with
PPFP peaks (FDR<0.05), after associating peaks with the gene having the nearest TSS. Nine of the
15 GO terms with the lowest q-values are related to immune function, development/differentiation,
or lipid metabolism, and the GO terms in the full list include additional cancer-related concepts
such as negative regulation of programmed cell death, regulation of cell migration, G1/S transition
of mitotic cell cycle, and Wnt receptor signaling pathway. In subsequent analyses, we focused on
gene sets that are both enriched in the ChIP-seq analysis and enriched among the differentially
expressed genes by RNA-seq analysis. Eight such gene sets were induced in PPFP cells versus
EV cells cultured without pioglitazone, and 13 were repressed (Table 4.4). Seven of the 8 induced
gene sets relate to mitochondria, and include direct PPARG target genes such as Plin1. The one
additional induced gene set, G1/S transition of mitotic cell cycle, includes genes such as Plk3 that
promote progression through the cell cycle and cell division. The inductions of Plin1 and Plk3 were
confirmed at the protein level, as noted previously (Figure 4.2). In contrast, the 13 repressed gene
sets relate mostly to protein signaling (4 gene sets), morphogenesis/development/differentiation
(4 gene sets), and cell communication/extracellular matrix/adhesion (4 gene sets). The repressed
genes in these gene sets include the thyroid development genes Fgfr2 (Celli et al., 1998) and Hhex
(Martinez Barbera et al., 2000).
PPFP functions through its PAX8 DBD to repress gene sets when bound at a distance from
transcription start sites, but to induce gene sets when bound close to transcriptional start sites We
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classified PPFP peaks as to whether they contain a PAX8 motif or a PPARG motif, and whether they
are ≤10kb from a TSS or >10kb upstream from a TSS. We then performed gene set enrichment
analyses on these 4 groups of PPFP peaks using ChIP-Enrich (Welch et al., 2014) and compared the
results with the RNA-seq analysis of PPFP cells versus EV cells without pioglitazone. Analysis of
PPFP peaks with PAX8 motifs>10kb upstream from TSS’s yielded no gene sets that were enriched
with ChIP-seq peaks and induced by PPFP. However, 16 gene sets were enriched and repressed by
PPFP, encompassing 59 unique genes. This suggests that, when regulating gene sets through PAX8
motifs distant from the TSS, PPFP tends to act in a repressive manner. Furthermore, 11 of these 16
gene sets contain the words morphogenesis, development or organ formation (Table 4.5), implying
that the effects of PAX8 binding at a distance >10kb upstream from TSS’s are primarily anti-
differentiation effects of PPFP. In contrast, analysis of PPFP peaks with PAX8 motifs ≤10kb from
TSS’s yielded 4 gene sets that were enriched in the ChIP and induced by PPFP, and no gene sets
that were enriched and repressed. Thus, at the gene set level, there is a complete separation of
PPFP as a repressor when the target genes have peaks with PAX8 motifs >10kb upstream from
the TSS, versus an activator when the PAX8 peaks are ≤10kb. The 4 induced gene sets all relate
to mitochondria and lipids (Table 4.6), and contain 24 unique genes. In contrast to the analysis of
PPFP peaks with PAX8 motifs, analysis of peaks with PPARG motifs did not identify differences
in gene set activation versus repression based on distance from the TSS (data not shown).
4.3.6 Why is pioglitazone adipogenic in PPFP-expressing cells?
When mice with PPFP thyroid carcinomas are treated with pioglitazone, metastatic disease is
prevented and the primary thyroid tumors shrink markedly (Dobson et al., 2011). The most striking
part of the response is that pioglitazone is highly adipogenic, causing large accumulations of intra-
cellular lipid and the induction of numerous adipocyte PPARG target genes in the thyroids. In con-
trast, pioglitazone has no effect on the thyroid glands of control mice. The induction of adipocyte
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genes is a hallmark of the pioglitazone response in cultured PPFP cells as shown here, too (Ta-
ble 4.3). Since PPARG is the master regulator of adipogenesis, the data indicate that pioglitazone
turns PPFP into a strongly PPARG-like transcription factor. However, PPARG also is expressed in
macrophages, where it plays an important role in promoting an anti-inflammatory “M2” phenotype
(Corzo and Griffin, 2013). Why does PPFP favor the induction of an adipocyte phenotype over a
macrophage phenotype in the thyroid? To begin to understand this, we took advantage of the fact
that a PPARG ChIP-seq analysis has been published comparing a mouse adipocyte cell line with
mouse macrophages (Lefterova et al., 2010). This study thus identified genes with PPARG peaks
in mouse adipocytes but not macrophages, and vice versa. Using HomoloGene, we assessed the
overlap between mouse genes with a nearby (≤10kb from TSS) PPARG peak and rat genes with at
least one nearby PPFP peak. We found that PPFP binds near 34% of homologs with an adipocyte
PPARG peak versus only 25% of homologs with a macrophage PPARG peak (Supplemental Table
4.7, p=0.0022). The fact that PPFP in the thyroid preferentially binds to adipocyte PPARG target
genes likely underlies the observation that the pioglitazone response is adipocyte-like.
4.3.7 Why is pioglitazone therapeutic in the mouse model of PPFP thyroid carcinoma?
We reasoned that genes or pathways regulated in opposite directions by PPFP without piogli-
tazone versus PPFP with pioglitazone may be involved in the therapeutic efficacy of this drug.
We therefore identified GO or KEGG terms in our RNA-seq data that are both induced (or re-
pressed) in PPFP cells versus EV cells without pioglitazone, and repressed (or induced) in PPFP
cells with pioglitazone versus PPFP cells without pioglitazone. Only three gene sets qualified, and
all were induced by PPFP without pioglitazone and repressed by pioglitazone. The 3 gene sets
relate to oxidative stress: Glutathione metabolism (KEGG), peroxidase activity, (GO) and arachi-
donic acid metabolism (KEGG). There are 49 unique, differentially expressed genes within these
gene sets, including multiple glutathione peroxidases, glutathione reductase, glutathione synthase,
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glutathione S-transferases, and peroxiredoxins (Supplemental Table 4.8). Based on these data, we
hypothesized that PPFP induces oxidative stress and that pioglitazone impairs the ability of the cell
to mount an appropriate antioxidant response.
To assess this, we evaluated oxidative stress in PPFP and EV cells by flow cytometry after
treatment with the reactive oxygen species (ROS)-sensitive dye CellROX Deep Red. PPFP cells
had greater ROS than EV cells, cultured in the absence of pioglitazone (Figure 4.6A). Analysis of
PPFP cells cultured a low dose (50 µM ) of the reactive peroxide tert-butyl hydroperoxide (TBHP)
and pioglitazone showed that pioglitazone increased ROS in the presence of TBHP (Figure 4.6B)
but not in its absence (Figure 4.6C). In contrast, in EV cells, pioglitazone did not increase ROS
regardless of the presence or absence of TBHP (Figures 4.6D,E). These data support the hypothesis
that PPFP induces oxidative stress, and that pioglitazone increases the susceptibility of PPFP cells
to further oxidative stress. The data suggest that the therapeutic efficacy of pioglitazone in PPFP
thyroid cancer may at least in part relate to synergism with cellular stressors to induce oxidative
stress, cytotoxicity and ultimately, cell death.
4.3.8 Similarity of gene regulation by PPFP in PCCL3 cells and human thyroid carcinomas
To judge the clinical relevance of the PPFP cell ChIP-seq and RNA-seq analyses, it would be
ideal to compare these data to similar data from human PPFP carcinomas. However, human ChIP-
seq data would be difficult if not impossible to obtain due to the fact that antibodies to endogenous
PPFP also bind to PAX8 or PPARG (our PPFP is epitope-tagged), as well as the fact that PPFP
thyroid carcinomas are uncommon. Furthermore, the largest gene expression profiling study of hu-
man PPFP thyroid carcinomas included only 7 cases (Giordano et al., 2006). This study identified
275 genes that were differentially expressed in 7 PPFP follicular carcinomas versus 82 non-PPFP
thyroid tumors and 4 normal thyroids. Of those 275 genes, 264 have rat homologs, and we found
a 31% overlap with differential expression in our RNA-seq data and 22% overlap with our ChIP-
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seq data. This overlap includes numerous PPARG target genes, including ANGPTL4 and AQP7,
which were two of the six most highly induced genes in the human PPFP carcinomas. We also
found that the set of 49 ROS-related genes described above is induced in the 7 PPFP follicular car-
cinomas versus the non-PPFP follicular carcinomas (p= 0.0007, Fisher’s exact test, Supplemental
Table 4.9), suggesting that PPFP also causes increased ROS in human thyroid carcinomas.
4.4 Discussion
PPFP is an unusual oncoprotein in that it is the fusion of two transcription factors, PAX8 and
PPARG, and it retains the DBDs of both parent proteins. However, until now there were no studies
to determine whether PPFP actively bound both PAX8 and PPARG target genes. Gene expression
data in PPFP thyroid carcinomas also are very limited – the largest study included only 7 PPFP
carcinomas (Giordano et al., 2006), and given patient heterogeneity, only limited conclusions can
be drawn.
Here, we identified ∼ 20,000 putative PPFP binding sites in the rat PCCL3 cell line genome,
and found that these binding sites are enriched within -5 kb of transcription start sites and in
first introns. PPFP peaks encompass known PAX8 and PPARG binding sites, indicating that both
DBDs within PPFP are functional. Interestingly, PPFP preferentially binds to the subset of PAX8
peaks that also contain PPARG motifs, implying that the PPARG portion of PPFP is particularly
important in directing PPFP to its target genes. The fact that many PAX8 binding sites have a
nearby PPARG motif also suggests PPARG may play a role in normal thyroid biology. Thyroid-
specific deletion of murine PPARG has not been reported, but would provide a means to address
this question.
RNA-seq analysis shows that PPFP regulates the expression of ∼ 1500 genes in the absence of
pioglitazone and∼ 2000 genes in its presence. In general, pioglitazone reinforces PPFP-dependent
gene expression, but in 17% of cases it reverses the effects of PPFP. PPFP regulates many genes
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known to be regulated by PAX8 in thyrocytes or PPARG in adipocytes. For the latter, the gene
regulation by PPFP is particularly striking in the presence of pioglitazone. Although gene expres-
sion data in human PPFP thyroid carcinomas are very limited, there is excellent overlap between
the human data and our data, including the induction of PPARG target genes.
We identified an unusual dichotomy in the function of PPFP for genes with peaks contain-
ing PAX8 motifs. When such motifs are located >10kb upstream from the TSS, the functional
consequence tends to be gene set repression, including processes related to morphogenesis and
development. In contrast, when such peaks are close to the TSS, the consequence tends to be gene
set induction. This dichotomy likely reflects the summed activity of transcriptional activators and
repressors brought to the target gene, but the factors that determine these differences are unknown.
The data are relevant to the biology of PPFP in human thyroid cancer. For example, PPFP in-
duces gene sets related to the cell cycle, and represses gene sets related to differentiation. In a trans-
genic mouse model of PPFP thyroid carcinoma, pioglitazone was highly therapeutic (Dobson et al.,
2011), and this has led to a clinical trial in patients (clinicaltrials.gov identifier NCT01655719). A
remarkable aspect of this response is that the drug trans-differentiated the surviving thyroid cancer
cells into adipocyte-like cells. Our ChIP-seq data show that, in PCCL3 thyroid cells, PPFP binds to
adipocyte PPARG target genes in preference to macrophage PPARG target genes, likely explaining
why pioglitazone is specifically pro-adipogenic.
It is plausible that the therapeutic efficacy of pioglitazone is at least in part due to its adipogenic
pro-differentiation effects. However, our data uncovered another potential contributing factor. We
found that PPFP cells have higher expression of ROS-related genes than EV cells, and this reflects
higher levels of oxidative stress. Pioglitazone caused the PPFP cells to develop even greater levels
of ROS when exposed to a low dose of the reactive peroxide TBHP, indicating that pioglitazone
sensitizes PPFP cells to potential oxidant stressors. These data suggest pioglitazone might sensitize
PPFP thyroid cancers in vivo to oxidative stressors, leading to increased cytotoxicity and cell death.
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Substantiation of this hypothesis could lead to approaches to further enhance the efficacy of this
drug.
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Figure 4.1: Venn diagram illustrating the overlap of genes regulated by PPFP in comparisons
of PPFP and EV cells cultured with and without pioglitazone. The total number of differentially
expressed genes for each comparison is shown in parentheses, using FDR<.05 and fold change>2
as cut-offs.
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Figure 4.2: Western blot analysis and RNA-seq expression data of selected genes in PPFP
and EV cells cultured without and with pioglitazone. RNA-seq data are normalized relative to
EV cells cultured without pioglitazone. The genes are organized by concepts related to the gene
set names with which they are associated, as described in Results. Although grouped together in
one figure, the expression of these proteins without and with pioglitazone is presented at several
different places within Results. (data generated by Bin Xu)
125
0
50
100
150
200
250
300
50 100 1500
0
50
100
150
200
50 100 1500
N
u
m
b
e
r
Propidium Iodide Propidium Iodide
EV cells PPFP cells
G1
G2
S
G1
G2
S
Figure 4.3: DNA content analysis of EV and PPFP cells. Cells were fixed, stained with pro-
pidium iodide and analyzed by flow cytometry using ModFit LT version 4.1 software. The graphs
show the histograms and the derived areas of the G1, S and G2/M (labeled G2) phases of the cell
cycle. These are quantified for EV cells as G1 45%, S 36% and G2/M 19%; and for PPFP cells,
G1 26%, S 43% and G2/M 31% of cells. (data generated by Jingcheng Yu)
126
0.7-
0.6-
0.5-
0.4-
0.3-
0.2-
0.1-
0.0-
F
ra
c
ti
o
n
IntergenicIntronUTRExon-5to-10kb-1to-5kb-1to+1kb
2.9 2.0 1.6
1.6
1.4
2.0
0.8
0.16-
0.12-
0.08-
0.04-
0.0-
F
ra
c
ti
o
n
>=4th3rd2nd1st
1.7
1.6
1.3
1.2
A
B PPFP peaks
Randomly generated peaks
PPFP peaks
Randomly generated peaks
Figure 4.4: Annotation of PPFP peaks versus randomly generated peaks, relative to genic
and intergenic regions. A. Peaks were assigned to one region only with the prioritization going
from left to right. B. The intron group of A is divided into individual introns. The numbers above
the bars indicate the ratios of PPFP to randomly generated peaks.
127
7111
3272
PPARG
6645
PAX8
3249
PPFP peaks, total 20277
A
PPARG spatial resolution 
in both-motif peaks
PAX8 spatial resolution 
in both-motif peaks
B
C
bp from peak center bp from peak center
-150 -50 0 50 150 -150 -50 0 50 150
D
e
n
s
it
y
0
.0
0
0
0
.0
0
2
0
.0
0
4
0
.0
0
6
0
.0
0
0
0
.0
0
2
0
.0
0
4
PPARG motif
PAX8 motif
Peaks
Random
Peaks
Random
Figure 4.5: PPFP peaks contain PAX8 and/or PPARG motifs. A. Venn diagram showing the
overlap of PAX8 and PPARG motifs within PPFP peaks, and the logos for PAX8 and PPARG
motifs. B. Spatial resolution analysis showing that both the PAX8 and PPARG motifs are centered
in the PPFP peaks that contain both motifs (black lines). The grey lines show the flat distribution
of each motif in randomly sampled 300bp regions across genome, serving as negative controls.
C. The peaks with PAX8 motifs identified in a previously published [23] PAX8 ChIP-seq analysis
of PCCL3 cells were divided into those that overlap or not with the PPFP peaks identified in this
study. These were then subdivided into peaks with or without PPARG motifs. PPARG motifs are
enriched in the PAX8 peaks that overlap with PPFP peaks, p<2.2e-16, Fisher’s exact test.
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Figure 4.6: Analysis of oxidative stress in PPFP and EV cells. The cells were incubated with
the reactive oxygen species-sensitive dye CellROX Deep Red and analyzed by flow cytometry. A.
PPFP cells have increase ROS relative to EV cells (cultured without pioglitazone). B. Pioglitazone
(pio) increases ROS in PPFP cells cultured with tert-butyl hydroperoxide (TBHP). C. Pioglitazone
does not increase ROS in PPFP cells cultured without TBHP. D, E. Pioglitazone does not increase
ROS in EV cells. All cells (A-E) were cultured and analyzed at the same time. The EV cell tracing
in A is the same preparation of cells as shown in E without pioglitazone, and the PPFP cell tracing
in A is the same as that in C without pioglitazone. (data generated by Jingcheng Yu)
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Tables
Table 4.1: Fifteen induced and 15 repressed gene sets with the lowest q-values in PPFP cells
versus EV cells cultured without pioglitazone
Concept.ID Concept.name p-value q-value Status
PPFP vs
EV
GO:0071346 cellular response to interferon-gamma 6.17E-07 1.37E-04 up
GO:0030529 ribonucleoprotein complex 8.09E-06 1.71E-04 up
GO:0005740 mitochondrial envelope 5.07E-05 6.49E-04 up
GO:0005811 lipid particle 8.27E-05 8.87E-04 up
GO:0046689 response to mercury ion 1.72E-05 1.05E-03 up
GO:0005730 nucleolus 2.08E-04 2.04E-03 up
GO:0004364 glutathione transferase activity 3.24E-05 2.25E-03 up
rno00480 Glutathione metabolism 1.29E-05 2.48E-03 up
GO:0042555 MCM complex 2.92E-04 2.54E-03 up
GO:0071219 cellular response to molecule of bacterial origin 6.99E-05 2.75E-03 up
GO:0071398 cellular response to fatty acid 1.02E-04 3.35E-03 up
GO:0006396 RNA processing 1.22E-04 3.56E-03 up
GO:0071384 cellular response to corticosteroid stimulus 1.23E-04 3.56E-03 up
GO:0000502 proteasome complex 5.06E-04 3.95E-03 up
GO:0006457 protein folding 2.13E-04 5.08E-03 up
GO:0008021 synaptic vesicle 1.36E-14 6.25E-12 down
GO:0007267 cell-cell signaling 1.98E-09 7.03E-06 down
GO:0004888 transmembrane signaling receptor activity 3.96E-08 2.75E-05 down
GO:0048858 cell projection morphogenesis 3.74E-08 2.95E-05 down
GO:0048730 epidermis morphogenesis 4.75E-08 2.95E-05 down
GO:0044306 neuron projection terminus 1.12E-06 3.45E-05 down
GO:0050808 synapse organization 1.10E-07 4.87E-05 down
GO:0048667 cell morphogenesis involved in neuron differentiation 1.38E-07 4.92E-05 down
GO:0004872 receptor activity 1.56E-07 5.40E-05 down
GO:0043534 blood vessel endothelial cell migration 2.87E-07 8.80E-05 down
GO:1901342 regulation of vasculature development 5.06E-07 1.28E-04 down
GO:0045995 regulation of embryonic development 1.15E-06 1.77E-04 down
GO:0090288 negative regulation of cellular response to growth fac-
tor stimulus
2.02E-06 2.55E-04 down
GO:0007167 enzyme linked receptor protein signaling pathway 2.91E-06 3.13E-04 down
GO:0051960 regulation of nervous system development 3.10E-06 3.24E-04 down
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Table 4.2: Regulation of PAX8-responsive genes by PPFP. In a previously published study of
PCCL3 cells (Ruiz-Llorente et al., 2012), siPAX8 regulated the expression of 296 genes by at
least 1.2-fold. This Table indicates how many of those genes are regulated by PPFP and in what
direction (PPFP cells versus EV cells, cultured without pioglitazone).
PPFP induces PPFP represses PPFP no change Total
siPAX8 induces 32 (18%) 62 (35%) 81 (46%) 175 (100%)
siPAX8 represses 47 (39%) 24 (20%) 50 (41%) 121 (100%)
Total 79 86 131 296
Table 4.3: The 10 induced gene sets with the lowest q-values in the comparison of PPFP cells
cultured with versus without pioglitazone all relate to fatty acid metabolism, mitochondria
and PPAR activity.
Gene set ID Description q-value
GO:0009062 fatty acid catabolic process 7.00E-11
GO:0019395 fatty acid oxidation 1.53E-10
GO:0004091 carboxylesterase activity 1.93E-09
rno03320 PPAR signaling pathway 4.55E-08
GO:0006637 acyl-CoA metabolic process 2.15E-07
GO:0006641 triglyceride metabolic process 4.81E-07
GO:0005777 peroxisome 5.61E-07
GO:0005740 mitochondrial envelope 5.96E-07
GO:0005759 mitochondrial matrix 1.03E-06
GO:0071398 cellular response to fatty acid 2.74E-06
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Table 4.4: Gene sets enriched in PPFP peaks by ChIP-seq analysis and differentially ex-
pressed in PPFP cells versus EV cells cultured without pioglitazone.
Gene set ID Description q-value
ChIP
q-value RNA-
seq PPFP vs
EV without pi-
oglitazone
Status
PPFP vs
EV
GO:0005740 mitochondrial envelope 0.024 6.49E-04 induced
GO:0044429 mitochondrial part 8.30E-04 7.19E-04 induced
GO:0005743 mitochondrial inner membrane 0.029 7.19E-04 induced
GO:0031966 mitochondrial membrane 0.029 8.51E-04 induced
GO:0005811 lipid particle 0.0088 8.87E-04 induced
GO:0019866 organelle inner membrane 0.024 9.99E-04 induced
GO:0019915 lipid storage 0.03 0.01 induced
GO:0000082 G1/S transition of mitotic cell cycle 0.01 0.042 induced
GO:0007167 enzyme linked receptor protein signaling
pathway
3.50E-04 3.13E-04 repressed
GO:0007169 transmembrane receptor protein tyrosine
kinase signaling pathway
0.011 0.0016 repressed
GO:0022603 regulation of anatomical structure morpho-
genesis
7.16E-04 0.0019 repressed
GO:0010648 negative regulation of cell communication 6.59E-04 0.0028 repressed
GO:0045664 regulation of neuron differentiation 0.035 0.0053 repressed
GO:0023057 negative regulation of signaling 0.0014 0.0072 repressed
GO:0009968 negative regulation of signal transduction 3.08E-04 0.008 repressed
GO:0031012 extracellular matrix 0.028 0.0081 repressed
GO:0035295 tube development 0.034 0.014 repressed
GO:0050867 positive regulation of cell activation 0.049 0.035 repressed
GO:0030155 regulation of cell adhesion 0.048 0.04 repressed
GO:0016331 morphogenesis of embryonic epithelium 0.042 0.043 repressed
GO:0005539 glycosaminoglycan binding 0.022 0.048 repressed
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Table 4.5: Gene sets enriched in PPFP peaks with PAX8 motifs >10kb upstream from TSS’s
and differentially expressed in PPFP cells versus EV cells without pioglitazone. All 16 gene
sets are repressed by PPFP.
Gene set ID Description q-value
ChIP
q-value RNA-
seq PPFP vs
EV without pi-
oglitazone
Status
PPFP vs
EV
GO:0048598 embryonic morphogenesis 0.017 0.0014 repressed
GO:0022603 regulation of anatomical structure morpho-
genesis
0.013 0.0019 repressed
GO:0003007 heart morphogenesis 0.04 0.0023 repressed
GO:0072358 cardiovascular system development 0.029 0.0036 repressed
GO:0035239 tube morphogenesis 0.019 0.0037 repressed
GO:0060562 epithelial tube morphogenesis 0.046 0.0049 repressed
GO:0031330 negative regulation of cellular catabolic
process
0.029 0.01 repressed
GO:0007507 heart development 0.016 0.013 repressed
GO:0035295 tube development 0.009 0.014 repressed
GO:0010463 mesenchymal cell proliferation 0.0041 0.017 repressed
GO:0048645 organ formation 0.025 0.019 repressed
GO:0061061 muscle structure development 0.037 0.022 repressed
GO:0051240 positive regulation of multicellular organ-
ismal process
0.038 0.023 repressed
GO:0009895 negative regulation of catabolic process 0.041 0.028 repressed
GO:0010464 regulation of mesenchymal cell prolifera-
tion
0.016 0.031 repressed
GO:0009887 organ morphogenesis 0.012 0.035 repressed
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Table 4.6: Gene sets enriched in PPFP peaks with PAX8 motifs ≤10 kb from TSS’s and
differentially expressed in PPFP cells versus EV cells without pioglitazone. All 4 gene sets are
induced by PPFP.
Gene set ID Description q-value
ChIP
q-value RNA-
seq PPFP vs
EV without pi-
oglitazone
Status
PPFP vs
EV
GO:0005740 mitochondrial envelope 0.047 6.49E-04 induced
GO:0044429 mitochondrial part 0.033 7.19E-04 induced
GO:0031966 mitochondrial membrane 0.047 8.51E-04 induced
GO:0005811 lipid particle 0.011 8.87E-04 induced
Table 4.7: Overlap of PCCL3 PPFP peaks with PPARG peaks in mouse adipocytes and
macrophages. The PPARG ChIP-seq data are from Lefterova et al. (2010). P=0.0022, Fisher’s
exact test, two tailed.
Sample # of peaks # of peaks
≤10kb to TSS
# of peaks
with ho-
mologs
# overlap with
PPFP (rat)
PPFP (rat) 20277 3965 2809 -
PPARG (mouse
adipocyte)
2634 870 537 186 (34%)
PPARG (mouse
macrophage)
1961 661 411 104 (25%)
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Table 4.8: Genes in gene sets that are induced by PPFP and repressed by
pioglitazone. Three gene sets were induced in the comparison of PPFP cells
versus EV cells cultured without pioglitazone, and repressed in the comparison
of PPFP cells with pioglitazone versus PPFP cells without pioglitazone. The
gene sets are glutathione metabolism (KEGG), peroxidase activity (GO), and
arachidonic acid metabolism (KEGG). The 49 unique, significant genes within
these gene sets are listed in this table.
Symbol Description
Cbr1 carbonyl reductase 1
Cbr3 carbonyl reductase 3
Cyp4a8 cytochrome P450, family 4, subfamily a, polypeptide 8
Cyp4f17 cytochrome P450, family 4, subfamily f, polypeptide 17
Cyp4f5 cytochrome P450, family 4, subfamily f, polypeptide 5
Duox2 dual oxidase 2
Ephx2 epoxide hydrolase 2, cytoplasmic
Gclc glutamate-cysteine ligase, catalytic subunit
Gclm glutamate cysteine ligase, modifier subunit
Ggt6 gamma-glutamyl transferase 6
Ggt7 gamma-glutamyltransferase 7
Gpx2 glutathione peroxidase 2
Gpx4 glutathione peroxidase 4
Gpx8 glutathione peroxidase 8
Gsr glutathione reductase
Gss glutathione synthetase
Gsta4 glutathione S-transferase mu 2
Gstm2 glutathione S-transferase mu 2
Gstm7 glutathione S-transferase, mu 7
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Gsto1 glutathione S-transferase omega 1
Gstp1 glutathione S-transferase pi 1
Gstt1 glutathione S-transferase theta 1
Hpgds hematopoietic prostaglandin D synthase
Idh1 isocitrate dehydrogenase 1 (NADP+), soluble
Idh2 isocitrate dehydrogenase 2 (NADP+), mitochondrial
Iyd iodotyrosine deiodinase
LOC501110 similar to Glutathione S-transferase A1 (GTH1) (HA sub-
unit 1) (GST-epsilon) (GSTA1-1) (GST class-alpha)
Lta4h leukotriene A4 hydrolase
Mgst1 microsomal glutathione S-transferase 1
Mgst2 microsomal glutathione S-transferase 2
Odc1 ornithine decarboxylase 1
Park7 parkinson protein 7
Pla2g2d phospholipase A2, group IID
Pla2g4a phospholipase A2, group IVA (cytosolic, calcium-
dependent)
Pla2g5 phospholipase A2, group V
Prdx1 peroxiredoxin 1
Prdx2 peroxiredoxin 2
Prdx3 peroxiredoxin 3
Prdx4 peroxiredoxin 4
Prdx6 peroxiredoxin 6
Ptgs1 prostaglandin-endoperoxide synthase 1
Ptgs2 prostaglandin-endoperoxide synthase 2
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Rrm1 ribonucleotide reductase M1
Rrm2 ribonucleotide reductase M2
Rrm2b ribonucleotide reductase M2 B (TP53 inducible)
15-Sep selenoprotein 15
Srm spermidine synthase
Tpo thyroid peroxidase
Txndc17 thioredoxin domain containing 17
Table 4.9: A set of ROS-related genes is induced in human PPFP follicular carcinomas versus
non-PPFP follicular carcinomas. Three gene sets in our RNA-seq data were induced in PPFP
cells versus EV cells without pioglitazone, and repressed in PPFP cells with pioglitazone versus
PPFP cells without pioglitazone: glutathione metabolism (KEGG), peroxidase activity (GO), and
arachidonic acid metabolism (KEGG). There are 49 unique, differentially expressed genes within
these gene sets. We tested whether this set of genes is induced in human PPFP follicular carcinomas
versus non-PPFP follicular carcinomas by comparing the expression of all probesets for the 49
genes versus the probesets for all other genes in the human thyroid carcinoma Affymetrix study of
Giordano (Giordano et al., 2006).
PPFP carcinomas
expression greater
than non-PPFP
carcinomas
PPFP carcinomas
expression less
than non-PPFP
carcinomas
Total
Probesets for set of
ROS-related genes
35 13 48
All other probesets 9685 10248 19933
Total 9720 10261 19981
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CHAPTER V
Conclusions and future directions
5.1 Conclusions
High-throughput sequencing technologies have matured over the past decade and found their
applications in various research fields, including cancer biology. Although bioinformaticians are
still exploring novel analysis algorithms and building efficient software tools to meet the expanding
needs, the power of this technology has already brought cancer research into the new “genomics”
era. In this dissertation, I have contributed to the role bioinformatics plays in cancer research both
in terms of methods and tool development (by introducing a new ChIP-seq analysis pipeline, PePr)
and in terms of analysis of diverse omics data (by using PePr and other open-source bioinformatics
software tools to study molecular subtypes in head and neck cancers).
In Chapter 2, I introduced a ChIP-seq pipeline (PePr) to analyze replicated ChIP-seq data,
with the primary goal for differential binding analysis. PePr introduced many new functionalities
into the ChIP-seq analysis pipeline, such as a window-size estimation method to automatically
accommodate for different peak types (sharp or broad), a normalization strategy to account for
differences in IP efficiencies between libraries, and post-processing steps to remove false-positive
peaks. PePr has superior performance on both replicated transcription factor and histone modifica-
tion datasets when compared to the most widely used software tools at the time of publication, and
can also be used on pull-down DNA methylation datasets, such as those generated with MeDIP-seq
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or hmeDIP-seq.
In Chapter 3, I performed integrative analysis of RNA-seq and SNP-array datasets on head and
neck squamous cell carcinomas. We identified two robust HPV subtypes using gene expression-
based clustering. One subtype (HPV-KRT) has more keratinization, higher copy number of PIK3CA
and TP63, and lower immune response and mesenchymal differentiation compared to the other
subtype (HPV-IMU), suggesting our HPV subtype findings are similar to what has been reported
in Keck et al. (2015). However, unlike Keck et al, who used microarray data, we were able to more
deeply characterize the difference between the two subgroups by analyzing SNP-array data for
whole-genome CNAs and mining the RNA-seq data for HPV related information and expressed
single-base mutations. We found that HPV-KRT has more genic viral integration events (iden-
tified from host-virus fusion transcripts), more spliced E6*, less full-length E6 activity and less
E2/E4/E5 expression than HPV-IMU. In fact, based on a previous study of E6-regulated genes
(Duffy et al., 2003), the differential expression of genes (between the subgroups) involved in mes-
enchymal differentiation, keratinization and oxidation reduction pathways could all be explained
by the difference in E6 activity and splicing. In addition, we show that HPV-KRT has more chr3q
amplification and PIK3CA activating mutations, whereas HPV-IMU has more chr16q deletions.
Our preliminary analysis suggests that the two arm-level CNAs likely promote tumor survival
through two different mechanisms: duplication of oncogenes on chr3q versus deletion of tumor
suppressors on chr16q. Combined with other observed differences, we hypothesize the two sub-
types likely undergo two different paths of oncogenesis and will benefit from different personalized
treatment plans. For example, HPV-KRT may respond better to immunotherapy and drugs target-
ing oncogenes on chr3q such as PIK3CA and TP63, whereas HPV-IMU may benefit more from
drugs that suppress epithelial-to-mesenchymal transition and/or E6 activity.
In Chapter 4, we characterized the binding profiles of the fusion oncogene PPFP using ChIP-
seq data, demonstrating that binding domains of both the original proteins, PAX8 and PPARG, are
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functional in the rat PPFP-transfected PCCL3 cell line. Our integrative analysis of RNA-seq and
ChIP-seq data in the same cell line suggests that PPFP regulates genes in many pathways related
to cancer. The protein expression levels of representative genes selected from these pathways were
validated using Western blot. Several of our analyses could not have been possible without the use
of previously published datasets. For instance, by incorporating the ChIP-seq data from Lefterova
et al. (2010), we demonstrated that PPFP prefers to bind to adipocyte genes rather than macrophage
genes, explaining the strong adipocyte phenotype in the presence of pioglitazone; we also showed
PPFP regulates PAX8 response genes using a published siPAX8 study (Ruiz-Llorente et al., 2012).
Finally, we explored the mechanism of the therapeutic effect of pioglitazone in PPFP tumors, and
found that pioglitazone may reverse PPFP’s oncogenic effect by altering the cell’s oxidative stress.
5.2 Future directions
The software (PePr) and studies on head and neck cancers presented in this dissertation are
parts of ongoing research efforts, and will open up many opportunities for future research.
5.2.1 Chapter II
As the sequencing depth and sample sizes keep increasing for ChIP-seq and other types of pull
down experiments, the run time and memory usage of PePr will also linearly increase. Therefore,
improvements on memory management and run time should be made in order for this tool to
remain useful for the community. To reduce the memory usage, data could be preprocessed into
trunks instead of loading into memory simultaneously. There are two potential strategies to reduce
the run time. First, we could incorporate the python package “multiprocessing” to parallelize the
program. Secondly, we could optimize the most computationally intensive module (the dispersion
estimation) by finding a more efficient solver for finding the root for where the derivative of the
maximum likelihood function (equation 2.7) equals zero.
In terms of models, we could expand the differential binding analysis to allow a design ma-
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trix for multiple groups and/or covariates. Additional modules could be included to allow more
comprehensive analysis of the data. For example, a preprocess module could be added to assess
the data quality and immunoprecipitation efficiency; in addition to splitting the genome into tiling
windows, we could also support testing pre-defined genomic regions such as promoters, enhancers
and CpG islands. We can also expand our pipeline beyond supervised analysis to unsupervised
data exploration where group labels are not used. For example, we could first identify a list of
peaks from each sample, and then combine the peak list and count the reads in these regions, and
then perform unsupervised clustering on these samples and peaks to discover patterns.
5.2.2 Chapter III
We have identified and characterized the transcriptomic and genomic properties of two HPV(+)
HNSCC subtypes. However, the epigenomic landscape of HPV(+) tumors is also very interesting
and should be examined in light of our identified subtypes when such data become available. An-
other limitation of our study is its small sample size, which is due to the difficulty in collecting
samples that pass the quality requirements for sequencing. In order to expand our subtype study to
a larger patient cohort and eliminate the need to deep sequence all of the samples, we could build
a classification rule on a few key genetic and/or transcriptomic markers using machine learning
algorithms to predict the two HNSCC subtypes. For instance, we could build a custom chip to
measure these markers for the new tumor samples and predict their subtypes. Then using the pre-
dicted labels in the larger patient cohort, we can validate our subtype findings such as the difference
in E2/E4/E5 expression, E6 activity, chr3q and chr16q CNA, and core pathway differences. With
a larger patient cohort, we can also examine the correlation of the cluster membership with other
important clinical variables, such as N stage, lymph node metastasis and disease recurrence.
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5.2.3 Chapter IV
The PPFP protein contains both DNA binding domains (DBD) of PPARG and PAX8 and uses
both to bind to 20,000 sites over the rat genome. It would be interesting to know to what extent
each of the DBDs are contributing to its oncogenic effect. We could perform similar ChIP-seq
and RNA-seq analysis on the same cell line transfected with PPFP protein with mutations on
either of the DBDs, and investigate the change in the binding sites and expression profiles after
the mutation. A tumor is more than a homogenous population of abnormal cells, but a complex
mixture defined as the tumor microenvironment, consisting of the tumor cells and multiple normal
cell types (Hanahan and Weinberg, 2011). The conclusions drawn from the cell line above may not
apply to the complex tumor in vivo; and there may be novel effects in a tumor microenvironment,
such as infiltrating immune cells, that are absent in cell lines. Although our findings in the rat
cell line are mechanistically interesting and largely concordant with studies conducted in human
and mouse, we should validate and expand upon them in a more complex model system, such as a
mouse xenograft model and human primary tumors (though it is difficult to collect such tumors in
human), which would also help eliminate species-specific effects.
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APPENDIX A
Supplemental material for Chapter II
Versions and detailed parameters of the programs used: All programs were run under default
parameters if possible. Significance cut-offs for all programs are provided in Table S4. The shift
size and window size estimated for each dataset with PePr are provided in Table S5. For Separate
Analysis (SA) approaches, the final peak regions were defined as the intersection of the peaks
generated from all separate runs; the significance of each peak was defined as the average of the
ranks in all separate analyses. See details below:
PePr version 1.0.1: default parameters were used. For TFs:
PePr c chip_file i control_file f file_format
--peaktype=SHARP remove_artefacts
For H3K27me3:
PePr c chip_file i control_file f file_format --peaktype=BROAD
MACS version1.4.0rc2: default parameters were used.
macs14 -t chip_file -c control_file
SPP version 1.10.1:
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SPP was run with the ENCODE project IDR guidelines. IDR thresholds of 0.01 and 0.0025
were chosen for the original replicate threshold and pooled-pseudoreplicate threshold, respectively.
The optimum set was reported.
Rscript run_spp.R -c=chipSampleRep1.tagAlign.gz
-i=controlSampleRep0.tagAlign.gz
-npeak=300000 -odir=/peaks/reps -savr -savp -rf
-out=/stats/phantomPeakStatsReps.tab
MACS2 version 2.0.10.09132012:
MACS2 was run with the ENCODE project IDR guidelines. IDR thresholds of 0.01 and 0.0025
were chosen for the original replicate threshold and pooled-pseudoreplicate threshold, respectively.
The optimum set was reported.
macs2 callpeak -t chipSampleRep1.tagAlign.gz
-ccontrolSampleRep0.tagAlign.gz
-f BED -nchipSampleRep1_VS_controlSampleRep0 -g hs -p 1e-3
--to-large
ZINBA version 2.01:
The alignability function was run with the corresponding genome and read mappability file. A
default read extension of 90 was used. For histone data, the “broad” argument was given.
generateAlignability(,athresh=1,extension=90),
zinba(, refinepeaks=0,seq=chip_file, input=control_file,
filetype=’’bed’’, extension=90)
SICER version 1.1:
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Parameters recommended by the manual were used. The corresponding genome was used for
each experiment. A window size of 200 and gap size of 600 were used for broad peaks. The
fragment size was set to 150.
SICER.sh chip_file control_file .genome 2 200 150 0.8 600 1E-2
edgeR version 3.2.4:
edgeR-basic: First the reads were shifted (45bp) and counted in non-overlapping windows
(200bp). The read counts and group assignments were prepared in edgeR specified format and then
the following commands were applied. Windows passing the significance cut-off were deemed
eligible and then adjacent windows were merged to form a final peak list.
edgeR-plus: All of PePrs pre-processing (shift size and window size estimates) and post-
processing steps (removing artefacts) were applied using our default parameter settings.
y = DGEList(counts=counts,group = group)
y = calcNormFactors(y)
y<-estimateCommonDisp(y, rowsum.filter=5)
y<-estimateGLMTagwiseDisp(y,design)
fit_tag<-glmFit(y,design)
lrt.tagwise<-glmLRT(fit_tag,coef=2)
DiffBind version 1.10.0:
First, SICER was used to call peaks from each sample using the matching input samples as
controls. The resulting peak lists from all four samples were input to DiffBind, which generated
29510 pre-candidate regions. The following commands were then executed to search for differen-
tial binding regions:
hpv = dba(sampleSheet="diffbind_sample.csv")
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hpv = dba.count(hpv)
hpv = dba.contrast(hpv,hpv$masks$‘HPV-‘,
hpv$masks$‘HPV+‘, "HPV-", "HPV+")
For DESeq:
hpv =dba.analyze(hpv,method=DBA_DESEQ)
hpv.DB = dba.report(hpv,method=DBA_DESEQ)
And for edgeR:
hpv =dba.analyze(hpv,bReduceObjects=F)
hpv.DB = dba.report(hpv)
diffReps version 1.55.4:
Default parameters. An exact negative binomial test was used. Settings were slightly different
between TFs and H3K27me3. For transcription factors, the sharp option was enabled and a window
size of 200 was used:
diffReps.pl tr chip_file1 chip_file2 ...
-co control_file1 control_file2 ... -gname genome me nb
nsd sharp window 200
For H3K27me3, the default parameters were used (nsd=“broad” and window size 1000):
diffReps.pl tr chip_file1 chip_file2 ...
-co control_file1 control_file2 ... -gname genome me nb nsd
